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General introduction
 Extracellular nucleotides contribute to the local regulation ofvascular tone and play
important roles in pathophysiological processes, including diabetes, hypertension,
atherosclerosis, and vascular remodeling i'2' 3). Nucleotides are released from aggregated
platelets, from adventitial nerve and from activated endothelial cells and leucocytes in
response to various pro-inflammatory stimuli, cell death and tissue damage i' 4). These
nucleotide induce either vasoconstriction or vasodilation through cell surface purinergic (P2)
receptors 5'D. P2 receptors are located on cell surface, which belong to major two families of
P2Y and P2X receptors 6' 8). So far, characterizations of P2 receptors have been published of
seven P2X receptor subtypes (P2Xi-P2X7, ligand-gated ion channels) and eight P2Y receptor
subtypes (P2Yi, P2Y2, P2Y4, P2Y6, and P2Yii-P2Yi4, G protein-coupled receptors) 6' 8). P2X
receptors are exclusively activated by ATP, whereas P2Y receptors respond to both purine
(ATP and ADP) and pyrimidine (UTP and UDP) nucleotides " 3' 6' 8). Specifically, ATP is a
ligand for P2Xi-P2X7, P2Y2, P2Yii, and P2Yi3 receptors, whereas UTP is a ligand for P2Y2
and P2Y4 receptors i' 3' 6' 8). In the arterial system, extracellular nu61eotides lead to
vasoconstriction and increased blood pressure by the activation of both P2X and P2Y
receptors on smooth muscle cells i'3' 6' g' 9). Some important effects ofextracellular nucleotides
are mediated by the activation ofendothelial cells and the subsequent release of
endothelium-derived relaxing factors (EDRFs; e.g., vasodilation and decreased blood
pressure) i' 3' 6' 8' 9). Moreover, extracellular nucleotides release endothelium-derived
contracting factors (EDCFs) in some pathophysiological states iO• ii).
  Type 2 diabetes is associated with a markedly increased incidence ofcardiovascular
diseases i2). A growing body ofevidence indicates that endothelial dysfunction and smooth
muscle dysfunction are present in various regions ofthe vasculature in type 2 diabetes in both
humans and animal models i3'i8). Vascular tone is controlled by EDRFs and EDCFs i9-22).
Abnormality ofthis balance (viz. decreased production ofEDRFs but also increased amounts
ofEDCF) results in diabetic vasculopathy 22-24).
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  Vasoconstrictor prostanoids such as PGE2, PGF2ct, PGD2, and TXA2 are released via the
activation of arachidonic acid (AA) pathway. This pathway starts wnh the release of AA from
cellular phospholipids thought phospholipase A2 (PLA2) activation, and AA can be
metabolized by cyclooxygenases (COXs). COXs are generally considered that COX-1, in
most tissues, is expressed constitutively while COX-2 is mainly induced by inflammatory
stimuli. In the vascular system, COXs are expressed in both endothelial and vascular smooth
muscle cells. These COXs pathways are a source ofsuperoxide anions, which increase
endothelium-dependent contraction 25). COX-mediated EDCF diffuses to the underlying
smooth muscle and activates prostanoid receptors. The most important prostanoid receptor is
thromboxane-prostanoid (TP) receptor in endothelium-dependent contractions, which then
leads to an influx ofcalcium ion into smooth muscle cells.
  EDCF-mediated responses are observed not only in hypertension but also in diabetes, and
they possibly reflect premature aging ofvascular walls subjected to aggravated oxidative
stress 20' 22). The available information confirms that in humans EDCF-mediated responses
contribute to the blunting ofendothelium-dependent relaxation in aged subjects and in
essential hypertensive patients 22). Identification ofEDCF could therefore provide new
insights into the mechanism responsible for endothelial dysfunction, and could potentially
reveal new therapeutic targets for cardiovascular diseases.
 Among the prostanoids, PGE2 is an important and ubiquitously distributed vasoactive
eicosanoid, and has been reported to act as a vasodilator and a vasoconstrictor. The prostanoid
EP receptors are heterotrimetic G protein-coupled receptors (GPCRs) 26t28). PGE2 exerts a
broad range ofeffects including inhibition of smooth muscle cells (mediated by the EP2 and
EP4 receptor subtypes) and excitation of smooth muscle cells (mediated by the EP1 and EP3
receptor subtypes) 26'28).
 On the other hand, EDRFs include nitric oxide (NO), prostacyclin (PGI2) and
endothelium-derived hyperpolarizing factor (EDHF) 29). NO is a soluble gas which mediates
much ofthe endothelium's control ofvascular relaxation. NO is formed by NO synthase
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(NOS), the most important NOS isoform is endothelial NOS (eNOS) within the
cardiovascular system. In the regulation ofeNOS activity upon agonist stimulation, signal
transduction depends not only on Ca2'lcalmodulin but also on eNOS phosphorylation by
various kinases 30-32). Regulation ofeNOS is achieved by phosphorylation ofmultiple sites in
the protein. Phosphorylation at Serii77 stimulates eNOs activity 30'32), whereas
phosphorylation at Thr495 inhibits its activity 34). P2Yi and P2Y2 are major nucleotide
receptors on endothelial cells, and the activation ofthese receptors leads to vasodilation
mainly via NO pathway. The oxidative stress contributes endothelial dysfunction via reduced
NO bioavailability and increased COX activity
 Angiotensin II (ANG II) is a vasoactive peptide and also causes the increases of the
oxidative stress in the vascular system. Therefore, ANG II plays an important role in the
pathogenesis ofcardiovascular diseases associated with type 2 diabetes, such as hypertension
and atherosclerosis. Moreover, treatment with ANG II type 1 (ATi) receptor blockers (ARBs)
ofpatients with type 2 diabetes significantly improves both macro- and micro-vascular end
points, including nephropathy, retinopathy, and neuropathy 35). However, little information is
available to indicate whether ARBs could normalize purinergic signalling once the
progression of the disease process has begun.
 For the present study, I designed experiments to investigate the mechanisms underlying the
diabetes-related changes in the extracellular nucleotides-induced responses in superior
mesenteric arteries from rats. Extracellular nucleotides mediate activation ofendothelial cells
and the subsequent release ofEDRFs and EDCFs. I hypothesized that extracellular
nucleotides-mediated relaxations and contractjons would be dysfunction in chronic diabetes.
Therefore, I also investigated the effect of diabetes on the response to extracellular
nucleotides (ATP, UTP and ADP) in superior mesenteric artery isolated from rats.
 Finally, I examined whether purinergic signalling can be used as potential therapeutic targets
against diabetes-associated vascular diseases.
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Chapter 1
Pravastatin normalizes endothelium-derived contraction factor-mediated response via
suppression of Rho-kinase signalling in mesenteric artery from aged type 2 diabetic rat.
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Introduction
  Normal vascular endothelial fimction depends on a controlled balance between the
productionlrelease ofendothelium-derived relaxing (EDRF) and contracting (EDCF) factors i'
2). EDCF-mediated responses contribute to the endothelial dysfimction seen in various animal
models of ageing, diabetes and cardiovascular diseases 3' 4). Appropriate modulation of
EDCF-mediated signaling pathways might be expected to ameliorate endothelial dysfunction.
Such modulations would therefore be oftherapeutic interest in the treatment ofcardiovascular
diseases. However, the precise mechanisms underlying EDCF signalling in long-term type 2
diabetes mellitus (T2DM) remain unclear.
  Type 2 diabetes mellitus, which is associated with a markedly increased incidence of
cardiovascular diseases, is often part of an array ofcomplex abnormalities referred to as
`metabolic syndrome', which is frequently accompanied by an elevated blood pressure 5).
Otsuka Long-Evans Tokushima Fatty (OLETF) rats are an established model ofT2DM 6), and
there are several existing reports ofabnormalities ofvascular function in this model 7-9).
Kamata's laboratory previously demonstrated (1) that endotheliai dysfunction is present in the
mesenteric arteries ofaged OLETF rats, (2) that this may result from an imbalance between
endothelium-derived factors (reduced EDRF signalling and increased EDCF signalling) and
(3) that the mechanisms underlying this abnormality may involve increments in the activities
ofCOX-1 and COx-2 8• 9).
  Pravastatin, an inhibitor of3-hydroxy-3-methylglutaryl coenzyme A reductase, reduces
adverse cardiovascular events and retards the development ofdiabetes in humans with
hypercholesterolaemia iO). Moreover, pravastatin has been reported to have pleiotropic
vascular effects including inhibitions ofthe Rho-kinase activity and reactive oxygen species
(ROS) production that occur via decreased formation of isoprenoid intermediates, such as
farnesylpyrophosphate and geranylgeranylpyrophosphate ii' i2). Beneficial effects on adverse
cardiovascular events have been demonstrated in OLETF rats following continuous
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administration ofpravastatin from 5 to 6 weeks ofage (pre-insulin resistance stage) i3• i4).
Moreover, Kajikuri et al. i5) suggested that pravastatin might prevent or retard the
development ofendothelial dysfunction in coronary arteries in OLETF rats by inhibiting
endothelial superoxide production. However, it is unknown whether pravastatin would have
beneficial effects on EDCF-mediated signalling in the superior mesenteric artery in OLETF
rats ifit is administered when hyperglycaemia has already developed.
  For the present study, I designed experiments (1) to investigate the effect of4 week
treatment with pravastatin on EDCF-mediated responses in OLETF rats at the chronic stage
of T2DM and (2) to identify some of the molecular mechanisms involved.
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Reagents
  Phenylephrine (PE), NG-nitro-L-arginine (L-MSIA), nitro-blue tetrazolium (NBT) and an
antibody against P-actin were purchased from Sigma Chemical (St. Louis, MO, USA), while
acetylcholine chloride (ACh) was purchased from Daiichi-Sankyo Pharmaceuticals (Tokyo,
Japan). Y27632 was from Calbiochem (La Jolla, CA, USA). All drugs were dissolved in
saline. All concentrations are expressed as the final molar concentration ofthe base in the
organ bath. Horseradish peroxidase (HRP)-linked secondary anti-mouse or anti-rabbit
antibody was purchased from Promega (Madison, WI, USA), Antibodies against COX-1,
COX-2, mPGES1 and mPGES2 were from Cayman Chemical (Ann Arbor, MI, USA), while
antibodies against RhoA, ROCKI and ROCKII were obtained from BD Biosciences (San Jose,
CA, USA). Antibodies against phospho-Ezrin (Thr567)IRadixin (Thr56`)/Moesin (Thr558)
(PERM) and Ezrin/Radiximuoesin (ERM) were obtained from Chemicon (Danvers, rm,
USA).
Animals and experimental design
  5 week-old male rats [OLETF rats and Long-Evans Tokushima Otsuka (LETO) rats, a
genetic control for OLETF] were supplied by the Tokushima Research Institute (Otsuka
Pharmaceutical, Tokushima, Japan). All animals were allowed a standard laboratory diet (MF}
Oriental Yeast Industry, Tokyo, Japan) and water ad libitum in a controlled environment
(room temperature, 21-22 OC; room humidity, 50 Å} 50/o) until they were 56-60 weeks old.
Some OLETF rats were given pravastatin (10 mg kg-i per day, p.o.) i6' i7) for 4 weeks starting
at 52-56 weeks old. Thus, I studied three groups: pravastatin-untreated LETO and OLETF
groups and a pravastatin-treated OLETF group. This study was approved by the Hoshi
University Animal Care and Use Committee, and all experiments were conducted in
accordance both with `Guide for the Care and Use ofLaboratory Animals' published by the
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US National Institutes ofHealth and with `Guide for the Care and Use ofLaboratory Animals'
adopted by the Committee on the Care and Use ofLaboratory Animals ofHoshi University
(which is accredited by the Ministry ofEducation, Culture, Sports, Science and Technology,
Japan).
Measurement ofbloodgincose, cholesterot, M'glyceride, insulin and non-estenPedfatty
aeid, andbloodpressure
  Plasma parameters and systemic blood pressure were measured as described previously 8' 9i
i6). Briefly, the plasma glucose, cholesterol, triglyceride, high-density lipoprotein (HDL)
cholesterol and non-esterified fatty acid (NEFA) levels were each determined by the use ofa
commercially available enzyme kit (Wako Chemical Company, Osaka, Japan). Plasma insulin
was measured by enzyme immunoassay (Shibayagi, Gunma, Japan). After a given rat had
been in a constant-temperature box at 37 OC for a few minutes, its systolic blood pressure
(SBP) was measured by the tail-cuff method using a blood pressure analyser (BP-98A;
Softron, Tokyo, Japan).
Measurement ofisomeM'cforee
  Vascular isometric force was recorded as in previous papers 8' 9). At 56-60 weeks of age,
rats were killed in the morning (at 09:OO hours). The superior mesenteric artery was rapidly
removed and immersed in oxygenated, modified Krebs-Henseleit solution (KHS). This
solution consisted of(in mM) 1 18.0 NaCl, 4.7 KCI, 25.0 NaHC03, 1.8 CaC12, 1.2 NaH2P04,
1.2 MgS04 and 1 1.0 glucose. The artery was carefu11y cleaned ofall fat, and connective tissue
and ring segrnents 2 mm in length were suspended by a pair ofstainless steel pins in a
well-oxygenated (950/o 02-50/o C02) bath containing 10 mL ofKHS at 37 OC. The rings were
stretched until an optimal resting tension of 1.0 g was loaded, then allowed to equilibrate for
at least 60 min. Force generation was monitored by means of an isometric transducer (model
TB-61 IT; Nihon Kohden, Tokyo, Japan). For the relaxation studies, mesenteric rings were
pre-contracted with PE (1O-6 M). When the PE-induced contraction had reached a plateau
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level, ACh (1O-9-1O-5 M) was added in a cumulative manner. For the contraction studies,
mesenteric rings were first contracted using 80 mM K', these responses being taken as 1000/o.
There was no significant difference in the response to 80 mM K' among the LETO (n = 17),
OLETF (n = 17) and pravastatin-treated OLETF (n = 7) groups (1.62 Å} O.03, 1.77 Å} O.06 and
1 .81 Å} O. 1O g respectively). To aid examination of EDCF-mediated responses, rings were
treated with 1O-4 M L-NNA for 30 min to increase the amplitude ofendothelium-dependent
contractions i8). To investigate the effect of Rho-kinase on the EDCF-mediated response,
mesenteric rings were incubated for 30 min in a medium containing 10-6 or 10-7 M Y27632
plus 1O-4 M L-NNA before cumulative addition ofACh (10-8-10-5 M). After the addition of
sufficient aliquots ofthe agonist to produce the chosen concentration, a plateau response was
allowed to develop before the addition ofthe next dose ofthe same agonist.
Reletzse ofprostagtandins
  Prostanoid release was measured as in previous papers 8' 9). To allow us to measure this
release, mesenteric arteries from a given group were cut into transverse rings 4 mm in length.
These were placed for 30 min in siliconized tubes containing O.5 mL KHS in the presence of
10-4 M L-NNA at 37 OC, and then ACh (10-5 M) was applied for 15 min. Next, after the
mesenteric rings had been removed, the tubes were freeze-clamped in liquid nitrogen and
stored at -80 OC for later analysis. The prostaglandins were measured using a commercially
available EIA kit (Cayman Chemical). Ten-timediluted samples were used for measurements
ofPGE2. The various assays were performed as described in the manufacturer's procedure
booklet. Ihe amounts ofprostaglandins released are expressed as pg mg-i wet weight of
mesenterlc artery.
Mestern bloth'ng
  The protein levels ofthe COXs, mPGESs, RhoA, Rho-kinases, phosphorylated
Ezrin/RadixinlMoesin (PERM) and ERM were quantified using immunoblotting procedures,
essentially as described before 9).
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Western immunoblots for PERMIERM were obtained from mesenteric arteries after ACh
stimulation (10-5 M for 15 min in the presence ofL-NNA). Mesenteric arterial tissues were
homogenized in ice-cold lysis buffer containing 50 mM Tris-HCI (pH 7.2), 150 mM NaCl,
1O/o Nonidet P-40, 10/o sodium deoxycholate and O.10/o SDS containing protease- and
phosphatase- inhibitor cocktails (Complete Protease Inhibitor Cocktail and PhosSTOP; Roche
Diagnostics, Indianapolis, IN, USA). The lysate was cleared by centrifugation at l6,OOO g for
1O min at 4 OC. The supernatant was collected, and the proteins were solubilized in Laemmli's
buffer containing mercaptoethanol. Protein concentrations were determined by means ofa
bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL, USA). Samples (20 pg per
lane) were resolved by electrophoresis on 100/o SDSPAGE gels, then transferred onto
polyvinylidene difluoride (PVDF) membranes. Briefiy, after blocking the residual protein
sites on the membrane with PVDF blocking reagent (Toyobo, Osaka, Japan), the membrane
was incubated wnh rabbit anti-COX-1 (70 kl)a; 1 : IOOO), rabbit anti-COX-2 (72 ld)a; 1 :
1000), rabbit anti-mPGES1 (16 ld)a; 1 : 1000), rabbit anti-mPGES2 (33 kl)a; 1 : 1000),
mouse anti-RhoA (21 ld])a; 1 : 1000), mouse anti-Rho-kinasel (ROCKI) (160 kDa; 1 : 1000),
mouse anti-ROCKII (160 ld)a; 1 : 1000), rabbit anti-phospho-Ezrin (Thr56')/Radixin
(Thr56`)IMoesin (Thr558) (PERM) (85 kDa; 1 : 1000) or rabbit anti-ERM (85 kDa; 1 : 1000) in
blocking solution. HRP-conjugated, anti-mouse or anti-rabbit antibody was used at a 1 : 1O
OOO dilution in Tween PBS, followed by detection using SuperSignal (Pierce). To norrnalize
the data, I used P-actin as a housekeeping protein. The P-actin protein levels were determined
after stripping the membrane and probing with B-actin monoclonal primary antibody (42 kDa;
1 : 5000), with HRP-conjugated anti-mouse IgG as the secondary antibody. The optical
densities ofthe bands on the film were quantified using densitometry, with correction for the
optical density ofthe corresponding B-actin band.
Measurement ofsuperoxide by measurement ofthe amount ofNBT reduced
  Mesenteric artery rings were incubated with NBT to allow the superoxide generated by the
tissue to reduce the NBT to blue formazan. The details ofthe assay have been published
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previously 9). Briefly, mesenteric arteries from the LETO and pravastatin-treated and
untreated OLETF groups were cut into transverse rings 4 mm in length. Then, rings from a
given group were placed for 120 min in KHS at 37 OC containing NBT (1O-4 M) in the
presence ofACh (1O-5 M). The NBT reduction was stopped by the addition ofO.5 N HCI.
After this incubation, the rings were minced and homogenized in a mixture of O. 1 N NaOH
and O.1O/o SDS in water containing 40 mg L-i diethylenetriaminepentaacetic acid. After the
mixture had been centrifuged at 16,OOO g for 30 min, the resultant pellet was resuspended in
pyridine at 80 OC for 60 min to extract formazan. The mixture was then subjected to a second
centrifugation at 10,OOO g for 10 min. The absorbance ofthe formazan was determined
spectro-photometrically at 540 nm. The amount ofNBT reduced (=quantity of forrnazan) was
calculated as follows: amount ofNBT reduced == A Å~ V/(T Å~ Mt Å~ 6 Å~ b, where A is the
absorbance, Vis the volume ofpyridine, T is the time for which the rings were incubated with
NBT, Mt is the blotted wet weight ofthe arterial rings, s is the extinction coefficient (O.7 L
mmol-i mm-i) and l is the length ofthe light path. The results are reported in pmol min-i mg
Wt-i.
Statistical analysis
  Data are expressed as means Å} SE. Relaxation responses are expressed as a percentage of
the PE-induced contraction. Contractile responses are expressed as a percentage ofthe 80 mM
KCI-induced contraction. Multiple comparisons between treatment groups were made using
an analysis ofvariance (ANOVA) followed by Bonferroni's test (P Åq O.05 being regarded as
significant in each test).
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                              Abbreviations
ACh, acetylcholine; ANOVA, analysis ofvarience; COX, cyclooxygenase; DMSO,
dimethylsulfoxide; EDCF, endothelium-derived contracting; EDRF, endothelium-derived
relaxing; EP receptor, prostaglandin E2 receptor; ERM, EzrinlRadixinfMoesin; HDL,
high-density lipoprotein; HMGCoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A
reductase; HRP, Horseradish peroxidase; KHS, Krebs-Henseleit solution; LETO, Long-Evans
Tokushima Otsuka; L-NNA, NG-nitro-L-arginine; NO, nitric oxide; NOS, NO Synthase;
mPGES, microsomal prostaglandin E synthase; NBT, nitro--blue tetrazolium; NEFA,
non-esterified fatty acid; OLETF, Otsuka Long-Evans Tokushima Fatty; PE, phenylephrine;
PGE2, prostaglandin E2; PVDF, polyvinylidene difluoride; ROCK, Rho-kinase; SBP, systolic
blood pressure; SE, standard error; SDS-PAGE, sodium dodecyl sulfate-polyacryIamide gel
electrophoresis; T2DM, type 2 diabetes mellitus
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Results
Generatparameters
  As shown in Table 1-1, at the time ofthe experiment, all OLETF rats (non-fasted)
exhibited hyperglycaemia, their blood glucose concentrations being significantly higher than
those ofthe age-matched non-diabetic control LETO rats (also non-fasted). Body weight was
similar between the two groups. Plasma cholesterol, triglyceride, HDL and NEFA levels were
all significantly higher in OLETF rats than in LETO rats. The SBP ofOLEIF rats was higher
than that ofLETO rats. Treatment ofOLETF rats with pravastatin did not alter their plasma
glucose, insulin, cholesterol, triglyceride or HDL levels or their SBP, but it did lower plasma
NEFA.
Effeet ofpravtzstatin treatment on endothetium-dependent relexation and contraction in
OLETFrats
  When the PE-induced contraction had reached a plateau, ACh was applied to induce
relaxation (Fig. 1-IA). ACh induced a concentration-dependent relaxation (with the maximum
response being at 1O'7 to 3 Å~ 1O-7 M, and responses then being progressively weaker up to
1O-5 M), and this response was weaker in rings from OLETF rats than in those from LETO
rats (Fig. 1-IA). In rings from pravastatin-treated OLETF rats, the relaxation responses were
similar to those seen in the LETO group (Fig. 1-IA).
  To investigate the contractile component ofthe ACh-induced response, I added ACh (1O-8-
10-5 M) cumulatively to rings in the presence ofL-NNA (10-4 M). As shown in Figure 1-IB,
in this condition, an ACh-induced contraction was observed at higher ACh concentrations (i.e.
1O-6-1O-5 M) in rings from the three groups. However, this ACh-induced contraction was
significantly greater in mesenteric arteries from OLETF rats than in those from LETO rats.
Interestingly, it was reduced by 4 weeks treatment with pravastatin.
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Table 1-1. Values of various pararneters in LETO and pravastatin-treated and
OLETF rats.
-
untreated
LETO OLETF Pravastatin-treated
OLETF
Bodyweight(g) 554.7Å}5.9(16) 544.4Å}23.6(16) 522.1Å}9.9(16)
Glucose(mg/dl) 134.9Å}3.9(16) 542.8Å}20.1(16)* 556.3Å}44.0(16)*
Insulin(ngtml) 3.0Å}O.2(15) 2.3Å}O.5(15) 1.7Å}O.2(15)*
Cholesterol(mg/dl) 103.9Å}2.1(16) 281.3Å}14.1(16)* 262.5Å}24.4(16)*
Triglyceride
(mgtdl)
86.5Å}3.0(16) 487.1Å}46.5(16)* 513.7Å}82.2(16)*
HDL(mg/dl) 62.6Å}2.3(16) 95.5Å}8.0(16)* 106.0Å}92(16)*
NEFA(mEqll) O.28Å}O.Ol(16) O.53Å}O.02(16)* O.42Å}O.03(16)*#
SBP(mmHg) 117.5Å}2.2(16) 147.7Å}3.1(16)* 148.3Å}3.1(16)*
Values are means Å} S.E.M. Number of determinations is shown within parentheses. HDL,
high-density lipoprotein; NEFA, non-esterified fatty acid; SBP, systolic blood pressure. "P Åq
O.05 vs. LETO. #P Åq O.05 vs. OLETF.
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Fig. 1-1. Concentration-response curves for acetylcholine (ACh)-induced relaxation (A) and
contraction (B) ofisolated rings ofmesenteric arteries isolated from Long-Evans Tokushima
Otsuka (LETO), Otsuka Long-Evans Tokushima Fatty (OLETF) and pravastatin-treated
OLETF rats. (A) Ordinate shows relaxation as a percentage ofphenylephrine-induced
contraction. (B) Responses were obtained in the presence of 10-4 M L-NNA. Data are means
Å} SE from eight (A) or seven (B) experiments. "P Åq O.05 vs. LETO. "P Åq O.05 vs. OLETF.
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Effect ofRho-kintzse inhibitor on EDCF-mediated contraction
  Rho-kinase is involved in the pathogenetic modulation ofvascular tone i9' 20). Moreover,
the Rho-kinase pathway contributes to EDCF-mediated arterial responses in
pathophysiological states 20' 2i). I therefore assessed the effects ofthe Rho-kinase inhibitor
y27632 (1O-7 or 1O-6 M) on the ACh-induced contraction in the presence ofL-NNA(1O"4 M).
Pre-treatment ofrings from OLETF or LETO rats with Y27632 reduced the EDCF-mediated
contraction in a concentration-related manner (Fig. 1-2). It should be noted that the
quantitative difference in this contraction between the OLETF and LETO groups was
abolished at each concentration ofY27632 (Fig. 1-2).
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Fig. 1-2. Effect of Rho-kinase inhibitor on endothelium-dependent contraction in mesenteric
arteries obtained from Long-Evans Tokushima Otsuka (LETO) and Otsuka Long-Evans
Tokushima Fatty (OLETF) rats. (A, B) Effect of 1O-6 or 1O-' M Y27632 on acetylcholine
(ACh)-induced contraction in the presence of 1O-4 M L-NNA in mesenteric arteries isolated
from OLETF (A) and LETO (B) rats. Data are means Å} SE from eight experiments. "P Åq O.05
vs. without Y27632.
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Effect ofpravtLstatin treatment on COXpathway (assessed as release ofPGE2 andprotein
expressions ofCOXs and mPGESs)
  Published evidence indicates that overproduction of prostanoids contributes to vascular
dysfunction in diabetic arteries 9' 22' 23). Moreover, I previously found that PGE2 was the
prostanoid responsible for increased EDCF signalling in mesenteric arteries from OLETF rats
8' 9' 24). In view ofthese previous reports and the data we obtained using ACh (Fig. 1-1), I
hypothesized that treatment of OLETF rats with pravastatin would reduce the ACh-stimulated
release of PGE2 from mesenteric artery rings isolated from such rats (Fig. 1-3A), ACh (1O-5
M) evoked a release ofPGE2 that was significantly greater in rings from OLETF rats than in
those from LETO rats, As I had hypothesized, this release ofPGE2 was significantly smaller
in the pravastatin-treated OLETF group than in the untreated OLETF group.
  Next, to investigate the possible mechanisms underlying the beneficial effects of
pravastatin on the COX pathway in OLETF rats, I examined whether the protein expressions
ofCOXs and mPGESs in mesenteric arteries might be altered by pravastatin treatment (Fig.
1-3). Western blotting analysis ofmesenteric arteries from the three groups allowed detection
of immunoreactive proteins. COX-1 expression was significantly greater in the OLETF group
than in the LETO group (Fig, 1-3B), while the expressions of COX-2 and mPGES 1 were not
significantly increased in OLETF vs. LETO (Fig, 1-3C, D), The expression ofmPGES2 was
not different among the three groups ofrats (Fig. 1-3E). Treatment of OLETF rats with
pravastatin did not alter these protein levels (vs. OLETF),
18
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Effeet ofpravastatin on Rho-ke'ntzse activity
  Statins modulate Rho-kinase signalling in the vasculature 25' 26). To determine the effect of
pravastatin on the protein expressions ofRhoA, ROCKI and ROCKII i9), I performed
immunoblotting for these proteins in mesenteric arteries and made comparisons among the
three groups. Each ofthese protein levels was similar among the three groups (Fig. 1-4A, B). I
next measured the level ofphosphorylated ezrin, radixin and moesin (PERM). Those proteins
are Rho-kinase targets and reflect Rho-kinase activity 27'29), so measuring pERM is a way of
assessing Rho-kinase activity in ACh-stimulated rings. Western immunoblots were obtained
from mesenteric arteries after ACh stimulation (10-5 M for 15 min in the presence of 1O-4 M
L-NNA) (Fig. 1-4C). Total ERM expression was similar among the three groups (Fig. 1-4C).
However, the level ofPERM was significantly greater in the OLE"IF group than in the LETO
group and significantly lower in pravastatin-treated OLETF than in untreated OLETF (Fig.
1-4q.
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#P Åq O.05 vs. OLETF. n,s,, not significant.
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euanatication ofsmperoxide anion by measurement ofthe amount ofNBT reduced
  As superoxide leads to enhancements of EDCF-mediated contractions 30), I examined the
effect ofpravastatin on vascular superoxide generation by measuring the amount ofNBT
reduced by superoxide (Fig. 1-5). Mesenteric artery superoxide generation was significantly
greater in OLETF than in LETO and significantly reduced in the pravastatin-treated OLETF
group (vs. the untreated OLETF group).
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Fig. 1-5. Quantification ofmesenteric artery superoxide production by measurement of
amount ofreduced nitro-blue tetrazolium (NBT). Tissues were obtained from Long-Evans
Tokushima Otsuka (LETO), Otsuka Long-Evans Tokushima Fatty (OLETF) and
pravastatin-treated OLETF rats. Data are means Å} SE from six or ten experiments. "P Åq O.05
vs. LETO. #P Åq O.05 vs. OLETF.
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Discussion
  In this study, I have demonstrated that pravastatin improves EDCF signalling in mesenteric
arteries in rats at the chronic stage of experimental T2DM.
  Otsuka Long-Evans Tokushima Fatty rats manifest stable clinical and pathological features
that resemble human T2DM 6). Briefiy, OLETF rats are characterized by I) increasing body
weightjust after weaning, 2) a late onset ofhyperglycaemia (after 18 weeks old) and
diagnosable diabetes after 24 weeks old, 3) a hyperinsulinaemia that is present at 24 weeks
old and declines after 55 weeks old, and conversion to insulin-dependent diabetes after approx.
40 weeks old, and 4) increasing plasma cholesterol and triglyceride concentrations after 21
weeks of age. In the present study, I used aged OLETF rats (i.e. 56-60 weeks old), which are
then at the insulin-dependent stage ofdiabetes, to investigate EDCF-mediated signalling. I
used such rats because long-term diabetic conditions entail severe diabetic complications
associated with cardiovascular dysfunction and because previous studies have investigated the
preventive, not the therapeutic, effect ofpravastatin on vasoconstrictor-prostanoid sigrialling.
  Pravastatin and other statins have clear beneficial effects on the atherosclerosis mediated by
decreased LDL-cholesterol, and they improve endothelial function in part through their
anti-inflammatory actions 3i). Recent experimental and clinical evidence indicates that some
ofthe cholesterol-independent or `pleiotropic' effects of statins involve improvements or
restorations ofendothelial functions and reductions in cardiovascular disease events ii'32). As
regards such effects, it has been reported that statins inhibit the synthesis of isoprenoid
intermediates in the cholesterol synthesis pathway, such as geranylgeranylpyrophosphate and
farnesylpyrophosphate ii'32). These intermediates serve as important lipid attachments for the
post-translational modification ofa variety ofproteins, including such small GTPases as
RhoA and Rac1. RhoAfRho-kinase plays a crucial role in endothelial dysfunction, including
down-regulation ofeNOS protein expression, whereas Rac1 induces assembly ofthe
NADPH-oxidase complex, the most important source of the primordial oxygen radical in the
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vessel wall ii). Accordingly, statins reportedly ameliorate both hypertension and T2DM, with
or without hypercholesterolaemia, in patients and in several animal models 34' 35), indicating
that these diseases involve activation of RhoAIRho-kinase and increased superoxide
production.
  In OLETF rats, SBP and plasma glucose, cholesterol, triglyceride, HDL and NEFA
concentrations were all increased (vs. LETO). When I administered pravastatin for 4 weeks to
such established OLETF rats, the treatment did not alter (vs. OLETF) SBP or the plasma
glucose, insulin, cholesterol, triglyceride or HDL levels, although it did decrease the plasma
NEFA level. Pravastatin has been reported to improve both hypercholesterolaemia and insulin
sensitivity in diabetes, both in patients and in animal models 35). Moreover, several
experiments have demonstrated that it reduces blood pressure in hypertensive patients 36),
although in another report pravastatin did not affect blood pressure in angiotensin-II-induced
hypertensive mice 26). This discrepancy may be related to the model, to a species difference or
to the pravastatin treatment regimen i6' iD. possibly, ifOLETF rats were treated with
pravastatin for a long time, or if treatment was started at an earlier stage, this drug might
reduce the levels ofhypercholesterolaemia andlor hypertension and significantly improve
insulin sensitivity. In this study, I found that in OLETF mesenteric arteries (vs. LETO) 1)
ACh-induced relaxation was reduced, 2) both the EDCF-mediated contraction and PGE2
production induced by ACh were increased, as was the expression ofCOX-1, while the
expressions ofCOX-2 and mPGES1 were not sigriificantly increased, and 3) the
ACh-stimulated PERM level was increased. Using our regimen (viz. 4 week treatment of
OLETF rats already at the chronic stage), I found that pravastatin treatment normalized
ACh-induced relaxation, EDCF-mediated contraction and PGE2 production, and also the
PERM level, without changing the expressions of two COXs, two mPGESs, RhoA and two
Rho-kinases. Tojudge from these results, pravastatin exerted vasculoprotective actions in the
present OLETF mesenteric arteries that can be largely attributed to a suppression ofEDCF
signalling by a cholesterol-independent pleiotropic effect, such as a suppression of
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Rho-kinase.
   Endothelial dysfunction results not only from decreased EDRF signalling but also from
increased EDCF signalling. In aortas isolated from hypertensive rats 1) the ACh-induced
EDCF-mediated contraction was suppressed by pre-treatment with a superoxide scavenger
and 2) the H202-induced contraction was increased, and these responses could be inhibited by
Y27632, by a COX inhibitor or by a TP-receptor antagonist 2i). Indeed, in the hypertensive rat
aorta, the ACh-induced release ofendothelial COX-dependent ROS is augmented 30). From
such evidence, ideas have been proposed for the identity ofEDCF, including release ofPGE2,
as have suggestions that endothelium- dependent contraction may involve the production of
ROS, activation ofendothelial COX and a subsequent stimulation ofTP receptors located on
smooth muscle cells. Recent experiments have suggested that Rho-kinase may act as a
molecular switch, transducing signals from endothelium-derived prostaglandins and ROS 20'
2i). Rho-kinase activation upregulates NADPH-oxidase expression 3n, and Rho-kinase plays a
role in vascular smooth muscle contraction (via inhibition ofmyosin phosphatase 38). In the
present study, I found that the EDCF-mediated contraction was suppressed by Y27632 in both
the LETO and OLETF groups and that the difference between those groups in the magnitude
ofthat contraction was abolished by Y27632. I also found that in OLETF mesenteric arteries
I) the superoxide generation was suppressed by pravastatin treatment, 2) the PERM level was
reduced by pravastatin treatment, and 3) the RhoA, ROCKI and ROCKII protein expressions
were not altered by pravastatin treatment. These results suggest that in OLETF mesenteric
arteries, pravastatin can suppress EDCF-mediated signalling, an effect that may be
attributable to a suppression of the activities of Rhokinase and that may be associated with a
lowering ofsuperoxide production.
  There are limitations ofthe present study that should be admitted. As mentioned above, the
circulating NEFA level was increased in OLETF rats, and this elevated level was reduced by
the treatment with pravastatin. A possible interpretation ofthe present data is that the
endothelial dysfunction present in OLETF rats is attributed to an increase in blood NEFA, and
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that endothelial dysfunction is improved by pravastatin treatment at least in part through a
lowering of this parameter. Indeed, evidence of endothelial dysfunction has been observed in
various vessels in states in which there is an increment in the circulating level of free fatty
acids 39-4i). Moreover, in the present study, I used one dose ofpravastatin as reported
previously i6' iD. Several reports suggest that pravastatin has beneficial effects in various
disease states by using different dose regimens iO' i3-i5' 33' 35' 36' 42). However, to establish a
causal relationship and appropriate dose ofpravastatin would require research focusing, for
example, 1) on time-course alterations both in circulating substances and in endothelial
dysfunction in this model because this OLETF rat manifests symptoms ofmetabolic
syndrome 42'43), and 2) on comparison ofvarious doses ofpravastatin with regard to the
impact on endothelial dysfunction.
  I conclude that pravastatin may have beneficial effects against the enhancement of
EDCF-mediated signalling seen at the chronic stage of T2DM. The mechanism responsible
for the pravastatin-induced suppression of EDCF-mediated responses may involve an
inhibition of Rho-kinase activity and a reduction in superoxide generation. These findings not
only support the pleiotropic effects ofpravastatin previously demonstrated in 1arge
intervention studies in T2DM patients but also offer a credible explanation for the beneficial
effects that this drug has on the vascular system in T2DM.
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Chapter 2
 Mechanisms underlying akered extracellular nucleotide-induced contractions in
mesenteric arteries from rats in later-stage type 2 diabetes: effect ofANG II type 1
                         receptor antagonism.
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Introduction
  Extracellular nucleotides play important roles in physiological and pathological processes,
including the regulation ofvascular tone, atherosclerosis, and remodeling i' 2). These
nucleotides are released from endothelial cells in response to mechanical stimuli, such as
shear stress, and also in response to hypoxia, hyperoxia, or agonist stimulation i' 2).
Extracellular nucleotides act through cell surface receptors, which can be divided into P2Y
and P2X receptor families 3' 4). So far, characterizations have been published of seven P2X
receptor subtypes (P2Xi-P2X7, ligand-gated ion channels) and eight P2Y receptor subtypes
(P2Yi, P2Y2, P2Y4, P2Y6, and P2Yii-P2Yi4, G protein-coupled receptors) 3' 4). P2X receptors
are exclusively activated by ATP, whereas P2Y receptors respond to both purine (ATP and
ADP) and pyrimidine (UTP and UDP) nucleotides '-`). Specifically, ATP is a ligand for
P2Xi-P2X7, P2Y2, P2Yii, and P2Yi3 receptors, whereas UTP is a ligand for P2Y2 and P2Y4
receptors i-4). In the arterial system, extracellular nucleotides cause vasoconstriction and
increased blood pressure by the activation ofboth P2X and P2Y receptors on smooth muscle
cells i-5). Some important effects ofextracellular nucleotides are mediated by the activation of
endothelial cells and the subsequent release ofendothelium-derived relaxing factors (EDRFs;
e.g., vasodilation and decreased blood pressure) i-S). Moreover, extracellular nucleotides
release endothelium-derived contracting factors (EDCFs) in some pathophysiological states 6'
D.
  Type 2 diabetes is associated with a markedly increased incidence ofcardiovascular
diseases 8). Various animal models have been used to gain insights into the pathogenesis of
the vasculopathy associated with type 2 diabetes 8), and an accumulating body of evidence
indicates that endothelial dysfunction is seen in several regions ofthe vasculature in animals
and humans with type 2 diabetes 9-i4). For example, Kamata et al. 9"ii' i5) have previously
reported that abnormal endothelium-derived signalings [i.e., impaired EDRF signaling and
enhanced EDCF (vasoconstrictor prostanoids) signaling] exist in mesenteric arteries from
type 2 diabetic rats. However, many ofthe animal models exhibit features ofmetabolic
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syndrome other than diabetes itself, such as hyperlipidemia, obesity, or hypertension. This
makes it diffricult to assess the pathogenetic relevance ofeach ofthese confounding factors in
the development ofdiabetic vasculopathy in these models. The Goto-Kakizaki (GK) rat offers
a convenient model for the study oftype 2 diabetes without the confounding effects ofobesity
or hypertension i6). GK rats are a highly inbred strain ofWistar rats that spontaneously
develop type 2 diabetes i6). This genetic rat model is panicularly usefu1 as a model ofhuman
type 2 diabetes because a defect in glucose-stimulated insulin secretion, peripheral insulin
resistance, hyperinsulinemia, and hyperglycemia are seen as early as 4 weeks after birth i6).
Although Kamata et al. i5' i7-i9) and others i3) have reported that abnormalities ofvascular
function exist in GK rats, no study on arterial reactivity to ATP, or the associated molecular
mechanisms, has been conducted using GK rats at the chronic stage ofdiabetes.
  Treatment with ANG II type 1 (ATI) receptor blockers (ARBs) in patients with type 2
diabetes significantly improves both macrovascular and microvascular end points, including
nephropathy, retinopathy, and neuropathy 20). Although various studies using animal models
ofcardiovascular diseases have demonstrated prevention ofdisease when treatment is started
before the onset ofcomplications, treatment ofdiabetic patients does not begin until after the
symptoms have been diagnosed 2i). Moreover, although several studies have demonstrated
that treatment with ARBs has beneficial effects on diabetic vasculopathy 20), little information
is available to indicate whether ARBs might normalize ATPIUTP-mediated signaling once
the progression ofthe disease process has begun.
  For the present study, I hypothesized that nucleotide-induced arterial contractions are
augmented in diabetic GK rats and, further, that treatment of such rats with an ARB (losartan)
would normalize these contractions. I designed experiments to investigate 1) the changes in
ATPIUTP-induced contractions ofmesenteric arteries that might occur as a result of
long-term diabetes, focusing especially on the relationship between nucleotide-induced
contractions and vasoconstrictor prostanoids signaling, and 2) the effects on these altered
nucleotide-induced contractions that might be seen ifrats had received short-term losartan
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treatment.
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Ex eriment
Reagents
  Phenylephrine, indomethacin, AJG-nitro-L-arginine (L-NNA), ATP (djsodium salt), 8,8'
-
carbonylbis(imino-3,1-phenylene carbonylimino)- bis(1,3,5-naphthalenetrisulfonic acid)
(NF-023), suramin, ct,B-methylene-ATP, nitroblue tetrazolium (NBT), and antibodies against
P2Y2, P2Y4, and P -actin were purchased from Sigma Chemical (St. Louis, MO). UTP
(trisodium salt) and arachidonyltrifluoromethyl ketone (AACOCF3) were from Wako (Osaka,
Japan). U-46619, valeroyl salicylate, NS-398, and antibodies against cyclooxygenase
(COX)-1 and COX-2 were from Cayman Chemical (Ann Arbor, MI).
5-Iodouridine-5'-O-diphosphate trisodium salt (MRS-2693) was obtained from Tocris
Bioscience (Ellisville, MO). Antibodies against cytosolic phospholipase A2 (cPLA2) and
phospho-cPLA2 were from Cell Signaling Technology (Danvers, MA), whereas the antibody
against P2Y6 was from Alomone Labs (Jerusalem, Israel). Drugs were dissolved in saline
except for AACOCF3, U-46619, valeroyl salicylate, and NS-398 (which were dissolved in
DMSO) and indomethacin (which was dissolved first in a small amount of O. 1 M Na2C03
solution and then made up to the final volume with distilled water). All concentrations are
expressed as the final molar concentration ofthe base in the organ bath.
Animats and experimental design
  Male Wistar control rats and GK rats were obtained at the age of4 weeks (Clea, Tokyo,
Japan). All animals were allowed a standard laboratory diet (MF, Oriental Yeast Industry,
Tokyo, Japan) and water ad libitum in a controlled environment (room temperature: 21-220C,
room humidity: 50 Å} 50/o) until they were 37-42 weeks old. Staning at 35-40 week old, some
GK and Wistar rats were given losartan for 2 weeks (25 mg•kg-i•day-i p.o. at 17:OO hours,
" Nulotan," Banyu, Ibarakj, Japan). Thus, I studied three groups: losartan-untreated Wistar and
GK groups and a losartan-treated GK group. This study was approved by the Hoshi
University Animal Care and Use Committee, and all experiments were conducted in
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accordance with the National Institutes ofHealth Guidefor the Care and Use ofLaboratory
Animals and with the "Guide for the Care and Use ofLaboratory Animals" adopted by the
Committee on the Care and Use ofLaboratory Animals ofHoshi University (which is
accredited by the Ministry ofEducation, Culture, Sports, Science, and Technology ofJapan).
Measurement ofblood glucose and insulin tevels and btoodpressure
  Plasma glucose and insulin levels were measured as previously described 9• iO• i5• i7'i9).
Briefly, the plasma glucose level was determined using a commercially available enzyme kit
(Wako). The plasma insulin level was measured by enzyme immunoassay (Shibayagi, Gunma,
Japan). After a given rat had been in a constant-temperature box at 370C for a few minutes, its
systolic blood pressure was measured by the tail-cuff method using a blood pressure analyzer
(BP-98A, Softron, Tokyo, Japan).
Metrsurement ofisomeM'eforce
  Vascular isometric force was recorded as in previous studies 9-i2' i5' i87 i9). At 3742 weeks
of age, some rats were euthanized each morning (at 09:OO hours). The superior mesenteric
artery was rapidly removed and immersed in oxygenated, modified Krebs-Henseleit solution
(KHS). This solution consisted of(in mM) 1 18.0 NaCl, 4.7 KCI, 25.0 NaHC03, 1.8 CaC12,
1.2 NaH2P04, 1.2 MgS04, and 1 1.0 glucose. The artery was carefuIIy cleaned ofall fat and
connective tissue, and ring segments of 2 mm in length were suspended by a pair of stainless
steel pins in a well-oxygenated (950/o 02-50/o C02) bath containing 1O ml KHS at 370C. Rings
were stretched until an optimal resting tension of 1.0 g was loaded and then allowed to
equilibrate for at least 60 min. Force generation was monitored by means of an isometric
transducer (model TB-61 1T, Nihon Kohden, Tokyo, Japan). In all experiments, tissues were
equilibrated for 30 min in the presence of 1O-4 M L-NNA before the administration of any
experimental agents. This was done because without this nitric oxide (NO) synthase (NOS)
inhibitor, nucleotide-induced contractions were too small for use in elucidating the
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mechanisms underlying the difference in responses to nucleotides between GK and Wistar
rats. For the contraction experiments, ATP (1O'6-1O-3 M), UTP (1O-7-1O-4 M), the selective
P2X agonist or,B-methylene-ATP [10-8-10-5 M 22' 23)], or the selective P2Y6 agonist
MRS-2693 [1O-8-3 Å~ 1O-5 M 24)] was added cumulatively to the bath until a maximal response
was achieved. To investigate the effects on the ATP- or UTP-induced contractile response
induced by drugs, a given ring was incubated for 30 min in the appropriate drug-containing
medium {viz. 10-6 M NF-023 [a P2Xi receptor antagonist 25' 26)], 1o-4 M suramin [a
nonselective P2 receptor antagonist 27' 28)], 1O-5 M indomethacin [a nonselective COX
inhibitor iO)], 3 Å~ 10-6M SQ-29548 [a TP receptor antagonist 29)], 10-4 M valeroyl salicylate
[a selective COX-1 inhibitor 30)], 10'6 M NS-398 [a selective COX-2 inhibitor 3i)], and 10-5 M
AACOCF3 [a cPLA2 inhibitor 32)]} before the cumulative addition of an agonist. When
required, removal ofthe endothelium from arterial segments was achieved by infusing
CHAPS (O.1O/o) for 60 s, which was subsequently flushed out with KHS; the inability ofACh
to relax these segments confirmed the success ofthis procedure. Finally, the wet weight ofthe
mesenteric ring was measured.
Release ofprostaglandins
  Prostanoid release was measured as in previous studies iO-i2). To allow us to measure this
release, mesenteric arteries from a given group were cut into transverse rings of4 mm in
length. These were placed for 30 min in siliconized tubes containing O.5 ml KHS in the
presence of 1O-4 M L-NNA at 370C and then further incubated with or without a given
nucleotide (3 Å~ 10-4 M ATP or 1O'4 M UTP) for 15 min. In some experiments, such
mesenteric rings (with or without endothelium) from GK and Wistar rats were incubated for
30 min at 370C in KHS containing 10-4 M L-NNA plus 10-5 M indomethacin, 10-4 M
valeroyl salicylate, or 10'6 M NS-398. Next, after the mesenteric rings had been removed, the
tubes were freeze clamped in liquid nitrogen and stored at -800C for later analysis.
Prostaglandins were measured using a commercially available enzyme immunoassay kit
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(Cayman Chemical). Ten time-diluted samples were used for measurements ofPGE2,
thromboxane B2 [TXB2; a stable metabolite ofthromboxane A2 (TXA2)], and PGF2., whereas
one hundred time-diluted samples were used for the meas.urement of6-keto PGFict, a stable
metabolite ofPGI2. The various assays were performed as described in the manufacturer's
procedure booklet. The amounts ofprostaglandins released are expressed as picograms or
nanograms per milligram of wet weight of the mesenteric artery.
Mestern blot analysis
  Protein levels of COX-1, COX-2, cPLA2, phospho-cPLA2, P2Y2, P2Y4, and P2Y6 were
quantified using immunoblot analysis procedures, essentially as previously described 9'i2• i8).
Mesenteric arterial tissues were homogenized in ice-cold lysis buffer containing 50 mM
Tris'HCI (pH 7.2), 150 mM NaCl, 10/o Nonidet P-40, 10/o sodium deoxycholate, and O.1O/o
SDS containing protease and phosphatase inhibitor cocktails (Complete Protease Inhibitor
Cocktail and PhosSTOP, Roche Diagnostics, Indianapolis, IN). The lysate was cleared by
centrifugation at 16,OOO g for 10 min at 40C. The supernatant was collected, and proteins were
solubilized in Laemmli's buffer containing mercaptoethanol. Protein concentrations were
determined using a bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL) and
kept the same in all samples. Samples (20 pgtlane) were resolved by electrophoresis on 100/o
SDS-PAGE gels and then transferred onto polyvinylidene difluoride (PVDF) membranes.
Briefly, after blockade ofresidual protein sites on the membrane with ImmunoBlock
(Dainipponpharm, Osaka, Japan) or PVDF blocking reagent (Toyobo, Osaka, Japan), the
membrane was incubated with anti-COX-1 (70 kl)a, 1: 1,OOO), anti-COX-2 (72 kDa, 1:1,OOO),
anti-cPLA2 (95 kl)a, 1:1,OOO), anti-phospho-cPLA2 (95 kDa, 1:1,OOO), anti-P2Y2 receptor (65
kl)a, 1:200), anti-P2Y4 receptor (78-79 kl)a, 1:300), or anti-P2Y6 receptor (42 kl)a, 1:200) in
blocking solution. Horseradish peroxidase-conjugated anti-rabbit antibody was used at a
1 : 10,OOO dilution in Tween-PBS followed by detection using SuperSignal (Pierce). To
normalize the data, we used B-actin as a housekeeping protein. B-Actin protein levels were
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determined after the membrane was stripped and probed with 6-actin monoclonal primary
antibody (42 kl])a, 1 :5,OOO) with horseradish peroxidase-conjugated anti-mouse IgG as the
secondary antibody. Optical densities ofthe bands on the film were quantified using
densitometry with correction for the optical density ofthe corresponding B-actin band. In
some experiments for COX protein detection, the same samples were loaded on the same gel
for COX-1, COX-2, and B-actin. Therefore, the P-acting loading control blot in figure
appeared to be the same (Fig. 2-6, A and B).
Measurement ofsuperoxide by metzsurement ofthe amount oflVBT reduced
  Mesenteric artery rings were incubated with NBT to allow the superoxide generated by the
tissue to reduce the NBT to blue formazan. Details ofthe assay have been published
previously i2). Briefly, mesenteric arteries from the Wistar and losartan-treated and -untreated
GK groups were cut into transverse rings of4 mm in Iength. Rings from a given group were
then placed for 120 min in 1 ml KHS at 370C containing NBT (10'4 M). The NBT reduction
was stopped by the addition ofO.5 N HCI (1 ml). After this incubation, rings were minced and
homogenized in a mixture ofO. 1 N NaOH and O. 1O/o SDS in water containing 40 mgll
diethylentriaminepentaacetic acid. The mixture was centrifuged at 16,OOO g for 30 min, and
the resultant pellet was resuspended in 250 pl pyridine at 800C for 60 min to extract formazan.
The mixture was then subjected to a second centrifugation at 1O,OOO g for 1O min. The
absorbance ofthe formazan was determined spectrophotometrically at 540 nm. The amount of
NBT reduced (equal to the quantity of formazan) was calculated as follows: amount ofNBT
reduced== A Å~ Vl( T Å~ Wt Å~ e Å~ b, where A is the absorbance, V is the volume of pyridine, T is
the time for which the rings were incubated with NBT, Wt is the blotted wet weight of the
arterial rings, 6 is the extinction coefficient (O.7 1•mmol-i•mm-i), and l is the length ofthe
light path. Results are reported as picomoles per minute per milligram wet weight.
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Statistieal analysis
  Data are expressed as means Å} SE. The contractile force developed by mesenteric artery
rings is expressed in milligrams oftension per milligram oftissue. Concentration-response
curves were analyzed by two-way ANOVA for repeated measures, and multiple comparisons
between treatment groups were made using ANOVA followed by Bonferroni's test (with P Åq
O.05 being regarded as significant in each test).
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                              Abbreviations
6-keto-PGF1,, 6-keto- prostaglandin Fi.; AA, arachidonic acid; ACh, acetylcholine; ANG,
angiotensin ; ANOVA, analysis ofvarience; ARB, ANG II type 1 receptor blocker; ATP;
adenosine triphosphate; CHAPS,
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate solution; COX,
cyclooxygenase; cPLA2, cytosolic Ca2'-dependent phospholipase A2; DMSO,
dimethylsulfoxide; EC, endothelial cell; EDCF, endothelium-derived contracting; EDRF,
endothelium-derived relaxing; GK, Goto-Kakizaki, HRP, Horseradish peroxidase; KHS,
Krebs-Henseleit solution; L-NNA, NG-nitro-L-arginine; NO, nitric oxide; NOS, NO Synthase;
NBT, nitro-blue tetrazolium; P2 receptor, purinoceptor; PE, phenylephrine; PGE2,
prostaglahdin E21 PGF2., prostaglandin F2. ; PVDF, polyvinylidene difluoride; SBP, systolic
blood pressure; SE, standard error; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis; SMC, smooth muscle cell, T2DM, type 2 diabetes mellitus; TP receptor,
thromboxane receptor; TXA2, thromboxane A2; TXB2, thromboxane B2; UTP, uridine
triphosphate
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Results
General parameter s
  As shown in Table 2-1, body weight was significantly lower in GK rats than in Wistar rats,
whereas non-fasted blood glucose and insulin levels were significantly higher in GK rats than
in Wistar (also non-fasted). Treatment with losartan did not alter the above parameters in GK
rats. Systolic blood pressure was significantly lower in GK rats than in Wistar rats. Short-term
treatment with losartan lowered systolic blood pressure (vs. the untreated GK group).
Table 2-1. Values ofvarious parameters in Wistar and losartan-treated and -untreated GK rats.
Wistar GK Losartan-treated
GK
Bodyweight(g) 629.2Å}11.4(16) 415.7Å}4.8(16)* 394.7Å}4.6(16)*
Glucose(mg/dl) 177.7Å}6.3(16) 501.5Å}12.9(16)* 461.1Å}15.8(16)*
Insulin(nglml) 2.5Å}O.2(16) 4.7Å}O.3(16)* 4.0Å}O.3(16)*
SBP(mmHg) 119.1Å}2.6(16) 108.5Å}1.9(16)* 98.1Å}2.3(16)*#
Values are means Å} S.E.M. Number of determinations is shown within parentheses. SBP,
systolic blood pressure. *P Åq O.05 vs. Wistar. #P Åq O.05 vs. GK.
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Contractile responses to A TP
  Since ATP can stimulate the release ofNO, which plays an important role in the regulation
ofvascular tone and negatively modulates contraction, I investigated such contractions in the
presence ofa representative NOS inhibitor (1O-4 M L-NNA), which inhibits both basal and
agonist-induced NOS activity. As shown in Fig. 2-IF, I confirmed that in the absence of
L-NNA, cumulative administration ofATP (10-6-10-3 M) led to a small
concentration-dependent increase in tension in mesenteric artery rings from both Wistar and
GK rats (note the expanded ordinate scale in Fig. 2-1]F). At the highest ATP concentration
used (i.e., 10-3 M), this contraction was significantly greater in GK rats than in Wistar rats.
Although L-NNA enhanced the ATP-induced contraction in both groups (Fig. 2-1, A vs. F;
note the difference in ordinate scales), the ATP-induced contraction was significantly greater
in rings from GK rats than in those from Wistar in the presence ofL-NNA (Fig. 2-IA). The
ATP-induced contraction was reduced by endothelial denudation, and this suppressive effect
of endothelial denudation was larger in GK rats than in Wistar rats (Fig. 2- IA). Higher
concentrations ofATP induced contraction even in endothelium-denuded rings, and this
response, too, was greater in GK rats than in Wistar rats (Fig. 2-IA). The existence of such
endothelium-independent vasoconstriction at higher concentrations ofATP is consistent with
results obtained in a previous study D using a different vessel, the rat aorta.
  To investigate the possible involvement ofP2Xi or P2Y receptors in the ATP-induced
contraction, I examined the effects of antagonists of those receptors on the ATP-induced
contraction. Incubation with NF-023, a P2Xi receptor antagonist (1O-6 M), reduced the
ATP-induced contraction in both Wistar and GK groups (Fig. 2-IB). Likewise, incubation
with suramin, a nonselective P2 receptor antagonist (1O-4 M), reduced such contraction in
both Wistar and GK groups (Fig. 2-1C). It should be noted that in the presence ofNF-023, the
ATP-induced contraction was still significantly greater in rings from GK rats than in those
from Wistar rats (Fig. 2-IB), whereas in the presence ofsuramin, this contraction was similar
between the two groups (Fig. 2-1C). Suramin treatment did not affect the contractile
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responses induced by 1O-80 mM KCI or 10-9-10-5 M phenylephrine in mesenteric arteries
(data not shown).
  Since ATP induces the release not only ofNO but also ofEDCF in some vessels D, and
since previous reports 9'i2) suggested that EDCF (i.e., vasoconstrictor prostanoids) signaling is
altered in diabetic mesenteric arteries, we next examined whether the ATP-induced
contraction might be altered after the acute inhibition ofCOX or antagonism ofthe TP
receptor. Treatment with either 10-5 M indomethacin, a nonselective COX inhibitor, or 3Å~
1O-6 M SQ-29548, a TP receptor antagonist, reduced the ATP-induced contraction in both
Wistar and GK groups (Fig. 2-ID and E). Furthermore, incubation with indomethacin
abolished the difference between the two groups (Fig. 2-ID), as did treatment with SQ-29548
(Fig. 2-IE). To investigate the difference between Wistar and GK rats in the contraction
induced by P2X receptor activation, we cumulatively applied ct,6-methylene ATP, a selective
P2Xi agonist, to rings from GK and Wistar rats (Fig. 2-1G). The contraction induced by ct,B
-
methylene ATP was greater in the GK group than in the Wistar group. Moreover,
indomethacin did not affect such contractions in either group (Fig. 2-1G).
Fig. 2-1. Concentration-response curves for ATP-induced contractions in rings ofmesenteric
arteries obtained from Wistar and Goto-Kakizaki (GK) rats. (A-E) effects ofendothelial
denudation (-EC; A), the P2Xi receptor antagonist NF-023 (1O-6 M; B), the nonselective P2
receptor antagonist suramin (1O-4 M; C), the nonselective cyclooxygenase (COX) inhibitor
indomethacin (Indo; 10-5 M; D), and the TP receptor antagonist SQ-29548 (3 Å~ 10-6 M; E) on
ATP-induced contractions in the presence of 10-4 M NG-nitro-L-arginine (L-NNA). (F)
ATP-induced contractions in the absence of 1O-4 M L-NNA. (G) concentration-response
curves for P2Xi agonist (or,P-methylene ATP)-induced contractions in rings ofmesenteric
arteries obtained from Wistar and GK rats. Indo (1O-5 M) did not affect the ct,B-methylene
ATP-induced contraction in either the Wistar or GK group. The ordinate shows the increase
in tension (expressed in mg tensionlmg tissue) measured at the peak ofthe response. Note the
expanded ordinate scales in (F) and (G). Data are means Å} SE from 4-8 experiments. The
curves shown in (A) for the GK and Wistar groups are shown again in (B), (D), and (E). "P Åq
O.05 vs. the Wistar group in (A-F). "P Åq O.05 vs. the GK group in (A-F). tP Åq O.05, the
Wistar group vs. the Wistar group with endothelium denudation in A or the GK group with
NF--023 vs. the Wistar group with NF-023 in (B). iP Åq O.05, the GK group with endothelium
denudation vs. the Wistar group with endothelium denudation in (A). In (G), *P Åq O.05 vs. the
Wistar group and #P Åq O.05, the GK group with Indo vs. the Wistar group with Indo.
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Contractite responses induced by the P2Y receptor agonist
  I next looked for differences between Wistar and GK rats in the contractions induced by a
P2Y2 and P2Y4 receptor agonist. Cumulative administration ofUTP (1O-7-1OM4 M), a
P2Y21P2Y4 receptor agonist, induced contraction that was significantly greater in rings from
GK rats than in those from Wistar in the presence of 1O-4 M L-NNA (Fig. 2-2A). The
UTP-induced contraction was largely blocked by endothelial denudation, and this maneuver
abolished the difference between the two groups (Fig. 2-2A). The enhanced UTP-induced
contraction seen in the GK group was largely suppressed by suramin (Fig. 2-2B),
indomethacin (Fig. 2-2C), or SQ-29548 (Fig. 2-2D). Furthermore, each ofthese treatments
abolished the difference between the two groups. Like the ATP response, the UTP-induced
contraction was smal1 in the absence ofL-NNA treatment (Fig. 2-2E; note the expanded
ordinate scale). The contraction induced by another P2Y21P2Y4 agonist (UTPyS) in the
presence ofL-NNA was greater in the GK group than in the Wistar group (data not shown). A
selective P2Y6 receptor agonist (MRS-2693) induced a very small contraction in each group
(Fig. 2-2F; note the expanded ordinate scale).
  To assess the possible involvement ofthe cPLA21COX pathway in the enhanced
nucleotide-induced contractions in GK rats, mesenteric rings were preincubated for 30 min
with 1O-4 M valeroyl salicylate (a COX-1-selective inhibitor; Fig. 3, A and D), 10-6 M
NS-398 (a COX-2-selective inhibitor; Fig. 2-3, B and E), or 10-5 M AACOCF3 (a cPLA2
inhibitor; Fig. 2-3, C and F). Interestingly, the contractions induced by ATP (Fig. 2-3, A-C)
and UTP (Fig. 2-3, D-F) were significantly inhibited by each ofthese inhibitors. It should be
noted that in the presence of each inhibitor, however, the two nucleotide-induced contractions
were still significantly greater in rings from GK rats than in those from Wistar rats (Fig. 2-3).
42
A D
5A -gg g
tsi.C';E
ae2
g-
B
s --
2:{s
'si g
s}
g-
c
  eo
'2 goo
es.
- aXE
:e,oo
7
UTP {-k)g M)
4
s-
::
.'•'
-•
B.
eOE
a..e2
e-
E
  GK
- GK Suramin
O vvistar
O WistarSuramln
7
VTP (-log M}
4
GK
GK lndomethacin
Wistar
Wistarlrxiomethacin
s-28
sS
,g' .'
eOE
seg-
F
5-
,e S
g'O'E
!?
g-
7
GK
GK SQ29548
Wlstar
vvistarscRgMs
UTP (-tog M)
Without L-NNA
4
7
u'rp (-k)g M)
10
T
UTP (-log M}
" GK
O VVistar
4
4
o-o-o-or)-o-e'D
8
 7 65MRS2693 (-Iog M} 4
Fig. 2-2. Concentration-response curves for UTP-induced contractions in rings ofmesenteric
arteries obtained from Wistar and GK rats. (A-D) effects ofendothelial denudation (A), the
nonselective P2Y receptor antagonist suramin (1O-4 Ml B), the nonselective COX inhibitor
Indo (10-5 M; C), and the TP receptor antagonist SQ-29548 (3 Å~ 10-6 M; D) on UTP-induced
contractions in the presence of 1O-4 M L-NNA. (E) UTP-induced contractions in the absence
of 10-` M L-NNA. (F) MRS-2693 (selective P2Y6 agonist)-induced contractions in the
presence of 1O'4 M L-NNA. The ordinate shows the increase in tension (expressed in mg
tensionlmg tissue) measured at the peak ofthe response. Note the expanded ordinate scales in
(E) and (F). Data are means Å} SE from 4-8 experiments. 'P Åq O.05 vs. the Wistar group in
(A) and (B). "P Åq O.05 vs. the GK group in (A-D). tP Åq O.05, the Wistar group vs. the Wistar
group with endothelium denudation in (A).
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Fig. 2-3. Effects ofa specific COX-1 inhibitor [10-` M valeroyl salicylate (VAS); (A) and
(D)], a specific COX-2 inhibitor (1O'6 M NS-398; B and E), or a specific cystolic
phospholipase A2 (cPLA2) inhibitor [1O-5 M arachidonyltrifluoromethyl ketone (AACOCF3);
C and Il on ATP-induced (A-C) or UTP-induced (D-7I7) contractions in rings ofmesenteric
arteries isolated from Wistar and GK rats. Data are means Å} SE from 6 experiments. The
curves shown in (A) for GK and Wistar rats are shown again in (B) and (C). The curves
shown in (D) for GK and Wistar rats are shown again in (E) and (]F). "P Åq O.05 vs. the Wistar
group. #P Åq O.05 vs. the GK group. tP Åq O.05, the inhibitor--treated GK group vs. the
inhibitor-treated Wistar group.
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Effect ofshort-term treatment with losartan on A TP- or UTP-indueed contraction
  Kamata et al. 9' i5' i9) and others 33) have demonstrated that ARBs have beneficial effects on
vascular function in diabetic models. Moreover, I have previously reported that the mesenteric
artery ANG II content was increased in GK rats i9) and firrther that short-term losartan
treatment ofGK rats at the chronic stage ofdiabetes normalized both the
endothelin-1-induced contraction i9) and EDRF-mediated relaxation i5). To investigate the
effect on nucleotide-induced contractions caused by blockade ofthe ATi receptor, I
investigated the effect ofa 2-wk treatment with losartan on contractions (Fig. 2-4).
Surprisingly, the increased ATP-induced (Fig. 2-4A) and UTP-induced (Fig. 2-4B)
contractions were each strongly suppressed by such treatment in GK rats.
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Fig. 2-4. Short-term (2 weeks) treatment with losartan suppresses nucleotide-induced
contractions in GK rats. (A) and (B) concentration-response curves for ATP-induced (A) or
UTP-induced (B) contractions in rings ofmesenteric arteries obtained from Wistar, GK, and
losartan-treated GK rats. Data are means Å} SE from 8-12 experiments. *P Åq O.05, the GK
group vs. the Wistar group. #P Åq O.05, the losartan-treated GK group vs. the GK group.
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ATP- or UTP-stimulated release ofprostanoitis
  The results described above (see Figs. 2-1-2-3) could be consistent with the enhanced
nucleotide-induced contractions in GK rats being attributable to activation ofthe cPLA21COX
pathway. I therefore investigated the release ofprostanoids from mesenteric arteries isolated
from Wistar, GK, and losartan-treated GK rats (Fig. 2-5). In nonstimulated mesenteric rings,
the production ofPGE2 (Fig. 2-5A), PGF2. (Fig. 2-5B), 6-keto-PGFi. (a stable metabolite of
PGI2; Fig. 2-5C), and TXB2 (a stable metabolite of TXA2; Fig. 2-5D) did not differ among the
three groups. ATP (3 Å~ 1O-` M) and UTP (1O-` M) each induced the release of PGE2 (Fig.
2-5E) and PGF2. (Fig. 2-5G), and each response was significantly greater in GK rats than in
Wistar rats. Surprisingly, the UTP-induced release ofeach ofthose two prostanoids was
significantly reduced in the losartan-treated GK group. Neither the ATP-induced nor
UTP-induced production of6-keto-PGFi. differed among the Wistar, GK, and
losartan-treated GK groups (Fig. 2-5jF). The ATP-induced release ofTXB2 was greater in GK
rats than in Wistar rats, but this enhancement was not affected by losartan treatment (Fig.
2-5M.
  To examine the mechanism responsible for the nucleotide-induced release ofPGE2 from
GK mesenteric artery rings, I investigate the effects ofendothelial denudation and COX
inhibitors on ATP-induced (Fig. 2-5I) or UTP-induced (Fig. 2-5.I) PGE2 production. The
increased ATP stimulated PGE2 production seen in the GK group tended (but not
significantly) to be reduced by endothelial denudation, and it was significantly reduced by
indomethacin, valeroyl salicylate, and NS-398 (Fig. 2-51). The increased UTP-stimulated
PGE2 production seen in the GK group was significantly reduced by each ofthe four
maneuvers (endothelial denudation, indomethacin, valeroyl salicylate, and NS-398; Fig.
2-50.
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Fig. 2-5. Release ofprostanoids [PGE2 (A and E), PGF2. (B and G), 6-keto-PGFi. (a stable
metabolite of prostacyclin; C and ]F), and thromboxane (TX)B2 (a stable metabolite of TXA2;
D and H)] from rings of mesenteric arteries isolated from Wistar, GK, and losartan-treated
GK rats either without (A-D) or with (E-H) stimulation by 3 Å~ 1O-4 M ATP or lO'4 M UTP. J
and J: effects ofendothelial denudation or COX inhibitors (10-5 M lndo, 10-4 M VAS, or 10'6
M NS-398) on PGE2release from rings ofmesenteric arteries isolated from Wistar and GK
rats upon stimulation with either 3 Å~ 10-4 M ATP (D or 10-4 M UTP (.1). Data are means Å} SE
from 6--12 experiments. "P Åq O.05 vs. the Wistar group in (E), (G), and (H). #P Åq O.OS, the
losartan-treated GK group with UTP vs. the GK group with UTP in (E) and (G). ln (b and (,]),
*PÅq O.05 vs. the Wistar control group. #P Åq O.05 vs. the GK control group. tP Åq O.05 vs. the
Wistar group with endothelium denudation.
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Ercpression ofCOX-1, COX-2, phospho-cPLt42, and cPLA2
  To investigate the possible mechanisms underlying the above beneficial effects of losartan
on ATPIU'IP-mediated responses in mesenteric arteries from GK rats, I first examined the
protein expression ofCOX-1, COX-2, and cPLA2 (Fig. 2-6). The protein expressions of
COX-1 (Fig. 2-6A) and COX-2 (Fig. 2-6B) were each significantly greater in GK rats than in
Wistar rats, but losartan treatment reduced only the elevated COX-2 expression.
  cPLA2 is activated by a rise in cytosolic Ca2' induced by receptor stimulation and by its
own phosphorylation (Ser505) 34). I examined the expression ofphospho-cPLA2 after P2Y
stimulation. ln the GK group, ATP-stimulated and UTP-stimulated cPLA2 phosphorylation
levels were each significantly increased (vs. those in Wistar rats), and the UTP-induced
increase was completely normalized in the losartan-treated GK group (vs. the UrlP-stimulated
GK group; Fig. 2-6C). Expression of total cPLA2 was not different among the Wistar, GK,
and losartan-treated GK groups (data not shovvn).
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Fig. 2-6. A and B: analysis ofCOX-1 (A) and COX-2 (B) protein expressions in mesenteric
arteries from Wistar, GK, and losartan-treated GK rats, Data are means Å} SE from 6-8
experiments. *P Åq O,05 vs. the Wistar group. #P Åq O,05, the losartan-treated GK group vs. the
GK group. Top: representative Western blot is shown (The same samples were loaded on the
same gel for COX-1; COX-2, and B-actin. Therefore, the P-acting Ioading control blot in
figure appeared to be the same.) (C) Western blots for ATP (3 x 10-4 M)-induced or UTP
(10-4 M)-induced cPLA2 phosphorylation in mesenteric arteries obtained from Wistar, GK,
and Iosartan-treated GK rats. Ratios were calculated for the optical density ofphosphorylated
(p-)cPLA2 over that ofcPLA2, Data are means Å} SE from 6 experiments, "P Åq O,05 vs, the
corresponding Wistar group, #P Åq O.05, the losartan-treated GK group vs. the GK group, tP Åq
O,05, the losartan-treated GK group with UTP vs. the GK group with UTP.
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Expression ofP2Y2, P2Y4, andP2Y6 receptors
  I measured P2Y2, P2Y4, and P2Y6 receptor expressions in mesenteric arteries by
immunoblot analysis (Fig. 2-7). The expressions ofP2Y2 (Fig. 2-7A) and P2Y6 (Fig. 2-7C)
were each similar between GK and Wistar rats, whereas P2Y4 (Fig. 2-7B) expression was
lower in GK rats than in Wistar rats. Losartan treatment ofGK rats did not affect P2Y2 and
P2Y6 expressions, but it increased P2Y4 expression.
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Effeets oftosartan on superoxideproduction in GK rats
  Superoxide leads to an enhancement ofEDCF signaling 35-38). Here, I investigated the effect
of losartan treatment on superoxide generation from the nonstimulated mesenteric artery by
measuring the amount ofNBT reduced by superoxide (Fig. 2-8) i2' 39). Mesenteric artery
superoxide generation was i) significantly greater in rings from GK rats than in those from
Wistar rats and 2) significantly weaker in the losartan-treated GK group than in the
losartan-untreated GK group.
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Fig. 2-8. Quantification ofmesenteric artery superoxide production by measurement ofthe
amount ofreduced nitroblue tetrazolium (NBT). Tissues were obtained from Wistar, GK, and
losartan-treated GK rats. Data are means Å} SE from 5 or 6 experiments. *P Åq O.05, the GK
group vs. the Wistar group. #P Åq O.05, the losartan-treated GK group vs. the GK group.
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Fig. 2-9. Schematic diagram showing the possible pathways mediating the enhanced
nucleotide-induced contractions observed in superior mesenteric artery rings obtained from
type 2 diabetic GK rats. I suggest that this enhancement is due to 1) abnormal release of
prostanoids from the endothelium after P2Y receptor stimulation and 2) increased expressions
ofp-cPLA2, COX-1, and COX-2. In the present study, short-term losartan treatment ofsuch
diabetic rats normalized 1) the increased nucleotide-induced contractions and the levels of
PGE2 and PGF2ct release and 2) the expressions ofCOX-2 and p-cPLA2. AA, arachidonic
acid; EC, endothelial cell; SMC, smooth muscle cell.
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Discussion
  The main inference to be drawn from the present study is that in superior mesenteric
arteries, nucleotide-induced contractions are enhanced in type 2 diabetic GK rats (vs. their
nondiabetic controls). This enhancement may be due to I) abnormal release ofprostanoids
from the endothelium and 2) increases in the expressions ofphospho-cPLA2, COX-1, and
COX-2. Furthermore, short-term losartan treatment ofsuch diabetic rats normalized 1) the
increased nucleotide-induced contractions and the release of PGE2 and PGF2ct and 2) the
expressions ofCOX-2 and phospho-cPLA2. To help the reader follow the discussion ofthe
present results and the putative underlying mechanisms, I have included a schematic summary
ofthe pathways and interactions that may be involved (Fig. 2-9).
  The GK rat, a model oftype 2 diabetes without the confounding effects ofobesity or
hypertension i6), was used here at the chronic stage ofdiabetes (3742 weeks old) because
long-term diabetic conditions are associated with severe diabetic complications, including
cardiovascular dysfunction. lndeed, numerous reports i3' i5' i7-i9' 4042) have indicated that
abnormal vascular reactivity is present in vessels from GK rats at this chronic stage. However,
no previous study has investigated nucleotide-induced contractile responses and how the
relevant downstream pathways or receptor expressions might be altered in a long-term
diabetic state.
  In the present study, the ATP-induced contraction was enhanced in mesenteric arteries
isolated from such GK rats (vs. those from the controls) under conditions in which NOS
activity was inhibited. To investigate the mechanisms underlying this enhanced contraction, I
first focused on the relationship between ATP-induced contraction and EDCFs (viz.
vasoconstrictor prostanoids) because 1) ATP can release such factors D; 2) Kamata et al. 9-i2)
previously found that signaling mediated by these factors was abnomial in mesenteric arteries
from Otsuka Long-Evans Tokushima Fatty rats, another type 2 diabetic model; and 3)
ATP-induced (Fig. 2-IF) and UTP-induced (Fig. 2-2E) contractions were smaller in the
absence than in the presence ofNOS inhibitor treatment. Indeed, some previous studies 7' 29)
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have used an NOS inhibitor (1O-4 M L-NNA) in investigations ofEDCF signaling. Here, I
found that 1) the ATP-induced contraction was suppressed by endothelial denudation and by
COX inhibitors in both GK and Wistar rats, 2) ATP-stimulated prostanoid release (viz. PGE2,
PGF2ct, and TXA2) was increased in GK rats, and 3) COX-1 and COX-2 expressions were
increased in GK rats. Interestingly, indomethacin and the TP receptor antagonist SQ-29548
each abolished the difference in the AIP-induced contraction between the GK and Wistar
groups. These results suggest that the enhancement ofA'IP-induced contraction seen in type 2
diabetic mesenteric arteries may be attributable to increases in the COX-mediated release of
endothelium-derived prostanoids.
  It has previously been demonstrated that nucleotide-induced vasoconstriction is mediated
by P2X and P2Y receptors in various arteries i' 2). To investigate which receptors might be
responsible for the enhancement ofATP-induced contraction in GK mesenteric arteries, I
used several agonistslantagonists ofthese receptors. In vascular smooth muscle cells, P2Xi is
the dominant P2X subtype 43), although P2X2, P2X3, P2X4, and P2Xs have also been found 44'
45). NF-023 inhibits P2Xi receptors more effectively than P2X2, P2X3, or P2X4 receptors 46),
whereas ct,B-methylene ATP is a relatively selective agonist for P2Xi and P2X3 receptors 46).
I found that I) the contraction induced by ATP was suppressed by both NF-023 and suramin
[a nonselective p2 antagonist 27' 28' 47' 48)]; 2) suramin, but not NF-023, abolished the difference
between the GK and Wistar groups; 3) the ct,B -methylene ATP-induced contraction was
increased in the GK group versus the Wistar group, but this response was not changed by
indomethacin treatment in either group; and 4) the enhancement ofthe UTP (P2Y21P2Y4
agonist)-induced contraction seen in GK rats (vs. Wistar rats) was greatly suppressed by
endothelial denudation, suramin, indomethacin, and SQ-29548, and each of these four
maneuvers abolished the difference between the two groups. Taken together, these results
suggest that the enhancement ofATP-induced contraction seen in the GK mesenteric artery
may be attributable attributable to increased endothelium-derived vasoconstrictor prostanoid
signaling after activation ofthe P2Y receptor, rather than ofthe P2X receptor. Actually,
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several reports 49'5i) have suggested that activation ofthe P2Y receptor stimulates the
production ofprostanoids.
  Vascular endothelial cells reportedly express several subtypes ofP2Y receptors 43' 52). In the
present study, I found that 1) the contractions induced by P2Y21P2Y4 agonists (UTP or
UTPyS) were increased in the GK group; 2) a P2Y6 agonist induced only a very smal1
contraction that was similar between the two groups; and 3) expressions ofP2Y2 and P2Y6
were each similar between the two groups, whereas P2Y4 expression was reduced in the GK
mesenteric artery. Currently, it is not possible to make a proper study ofsingle P2 receptor
subtypes due to the lack of selective antagonists. From my experiments, I cannot completely
exclude the possibility that alterations in the P2 receptor might play a role in the enhancement
ofnucleotide-induced vasoconstrictions in the GK mesenteric artery. However, it seems more
likely that the pathway downstream ofP2 receptors is altered in diabetic mesenteric arteries.
  Prostanoids are released via the arachidonic acid (AA) pathway, which starts with PLA2
activation and leads to the release ofAA from cellular phospholipids. Here, I found that
nucleotide-induced contractions were reduced by AACOCF3, a potent and selective inhibitor
ofcPLA2. Moreover, both ATP-and UTP-stimulated cPLA2 phosphorylation (activation) were
increased in the GK group. COX- and endothelium-dependent contractions have been
reported in the arteries of several species in response to various agonists and substances 6' 36' 38'
53). In the present study, expressions ofCOX-1 and COX-2 were increased in mesenteric
arteries isolated from GK rats. Moreover, the increased nucleotide-induced contractions in
GK arteries were reduced by selective inhibitors ofeach ofthe COXs. The increased
nucleotide-stimulated PGE2 release seen in mesenteric arteries from GK rats was suppressed
by indomethacin (ATP or UTP stimulation), valeroyl salicylate (ATP or UTP stimulation),
and NS-398 (ATP or UTP stimulation). These results suggest that increased cPLA21COX
pathway activity contributes to the enhancement ofnucleotide-induced contractions seen in
mesenteric arteries from GK rats. It should be noted that neither ofthe selective inhibitors of
COX-1 or COX-2 abolished the differences in nucleotide-induced contractions between GK
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and Wistar rats, but that indomethacin did abolish these differences. I speculate that
activations ofCOX-1 and COXd-2 contribute synergistically to the enhancement of
nucleotide-induced vasoconstrictions in mesenteric arteries in diabetic rats. This idea is
supported by published evidence showing that in several arteries from individuals with type 2
diabetes or other disease conditions, EDCF signalings are mediated not only by COX-1
aCtivation but also by COX-2 activation 6• iO• 36• 38• 53).
  Although I am uncertain as to the precise mechanism underlying the above differences
between Wistar and GK rats in P2Y receptor expression and in the downstream components,
various changes related to the long-term diabetic state might be involved. For instance,
Thaning et al. 54) noted attenuated purinergic receptor function in type 2 diabetic patients,
whereas hypoglycemia induced P2Y4 upregulation 55). Furthermore, activation of cPLA2 can
be induced by high glucose 56), or insulin5D, or high ANG II 58) [which is increased in
mesenteric arteries from GK rats i9)]. Thus, it is possible that the abnormalities observed in
the P2Y receptor-dependent cPLA21COX pathway in GK arteries may have been secondary to
one or more ofthe above variables changing as a result ofthe long-term disease state present
in chronically diabetic GK rats. However, to establish a relationship between the levels of
extracellular nucleotides and P2Y receptor expressions andlor functions will require research
focusing, for example, on time course changes in the above factors in the diabetic state,
because extracellular nucleotide levels are altered in diabetic states i).
  ARBs are very effective, safe antihypertensive drugs with pleiotropic effects (such as
antiatherogenic, and antidiabetic, antiplatelet-aggregating effects) 59). A novel, intriguing, and
potentially important finding ofthe present study is that 2 weeks losartan treatment
normalized the enhanced contractile responses to nucleotides seen in GK arteries. In fact,
losartan improved 1) ATP- and UTP-induced contractions, 2) UTP-stimulated cPLA2
phosphorylation and the UTP-induced release ofPGE2 and PGF2., and 3) COX-2 expression,
all in arteries from GK rats at the established stage ofdiabetes. The above finding is
supported by evidence from some others models. For example, ANG II increases cPLA2
56
activity in vascular smooth muscle cells 58) as well as both COX-2 expression and PGE2
production in aortic fibroblasts from normotensive and hypertensive rats through ATi
receptors 60). Moreover, we 9) have previously reported that losartan treatment oftype 2
diabetic rats suppressed both EDCF-mediated contraction and prostanoid release in their
isolated mesenteric arteries. Together, the previous evidence and the present data suggest that
losartan normalizes nucleotide-induced contractions via suppression ofthe cPLA21COX
pathway.
  One possibility for the mechanism underlying the losartan-induced improvement of
nucleotide-mediated responses is that there may be a reduction in oxidative stress. There is a
number ofreports 6' 35' 37' 6i) suggesting that oxidative stress augments EDCF-mediated
responses. Indeed, I have preliminary evidence showing that nucleotide-induced
vasoconstrictions in mesenteric arteries from GK rats can be reduced by tempol (a superoxide
dismutase mimetic) or by apocynin [an inhibitor ofNAD(P)H oxidase] (unpublished
observations). Since previous reports 9' 62' 63) and the present data (Fig. 2-8) suggest that
losartan decreases oxidative stress, the normalization ofnucleotide-induced signaling by
losartan may be mediated by its antioxidative actions. As yet, it remains unclear whether there
is a direct relationship between the effects of losartan on responses mediated by nucleotides
and its effects on these cellular pathways. Funher investigations will be required on this point.
  Several limitations ofthe present study should be mentioned. In the mesenteric arteries of
our GK rats, there were differences between ATP and UTP in terms oftheir prostanoid
release profiles and in the effects oflosartan on the release ofprostanoids. As mentioned
above, it is not yet possible to study single P2 receptor subtypes due to the lack of selective
antagonists. The ligand-receptor interactions (activation) involved in nucleotide signaling are
generally complex. Most ofthese receptors are capable ofmediating responses to several
nucleotides, resulting in multiple receptors having overlapping ligand preferences 2' 3' 4).
Moreover, there is a possibility that release ofprostanoids may be induced by nucleotides in
cells other than endothelial cells. Indeed, there are reports 64' 65) ofprostanoid release in
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vascular smooth muscle cells. Without further studies, I cannot distinguish which P2 receptor
activated signaling (endothelial cells vs. smooth muscle cells) might contribute to the
enhanced nucleotide-induced vasoconstrictions present in GK diabetic mesenteric arteries.
  In conclusion, my study demonstrate that the enhanced ATP-induced contraction seen in
mesenteric arteries taken from GK rats at the chronic stage ofdiabetes is due to increased
cPLA21COX pathway activity and that ATi receptor antagonism normalizes the P2Y-induced
contraction in such arteries via a suppression ofthat pathway's activity. I believe that my
findings should stimulate further interest in the manipulation ofATP andlor ANG II signaling
as potential therapeutic targets in the battle against diabetes-associated vascular diseases.
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Chapter 3
Protein kinase C delta contributes to increase in EP3 agonist-induced contractioll in
         mesenteric arteries from type 2 diabetic Goto-Kakizaki rats.
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Introduction
    That prostaglandins (PGs) play important roles in the regulationlmaintenance ofvascular
function is well recognized i'D. Among the PGs, prostaglandin E2 (PGE2), an important and
ubiquitously distributed vasoactive eicosanoid, has been reported to be a potent vasodilator in
various vessels in both humans and experimental animals i' 3' 5). However, PGE2 may be a
vasoconstrictor in some vessels such as human pulmonary artery 8), guinea pig aorta 9),
porcine large cerebral arteries iO), rat aorta ii) and rat mesenteric artery i2). The actual
PGE2-mediated vascular response appears to depend on species and vessel type as well as on
conditions such as physiological and pathophysiological states. For those reasons, the precise
mechanisms mediating PGE2-induced vasocontraction have not been thoroughly explored.
    The prostanoid EP receptors are heterotrimetic G proteincoupled receptors (GPCRs) i'3'
5). PGE2 exerts a broad range ofeffects including inhibition ofsmooth muscle cells (mediated
by the EP2 and EP4 receptor subtypes) and excitation of smooth muscle cells (mediated by
the EP1 and EP3 receptor subtypes) i'3' 5). Concerning the signaliBg pathway mediating
PGE2-mediated vasocontractions, Shum et al. i3) reported that the EP3 receptor agonist
sulprostone induces a contraction in guinea pig aorta that can be inhibited by a Rho kinase
(ROCK) inhibitor. More recently, Kobayashi et al. i2) found that the vasocontraction induced
by EP3 receptor activation is mediated by Ca2'-independent pathways involving protein
kinase C (PKC) 6 and s and ROCK in a main branch ofrat mesenteric artery. However, the
details of the mechanisms underlying the PGE2-mediated vasocontraction in diabetic states
remain unclear.
  Type 2 diabetes is associated with a markedly increased incidence ofcardiovascular
diseases i4-i8). A growing body ofevidence indicates that endothelial dysfunction and smooth
muscle dysfunction are present in various regions ofthe vasculature in type 2 diabetes in both
humans and animal models i4-i6' i9-2i). For instance, Kamata et al. previously found in vessels
isolated from type 2 diabetic Goto-Kakizaki (GK) rats at the chronic stage ofdiabetes: J) that
endothelium-dependent relaxation and endothelial nitric oxide synthase (eNOS) activity were
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impaired in the aorta 22' 23), 2) that endothelium-dependent relaxation was impaired in superior
mesenteric arteries 24' 25) and 3) that although endothelin- 1 (ET-1)-induced contraction was
increased in superior mesenteric arteries, angiotensin II- and arginine vasopressin-induced
contractions were similar between the GK and Wistar arteries 2i). Kamata's laboratory
proposed that upregulation of the ETA receptor, a defect in ETB receptor-mediated NO
signaling, and activation ofthe MEKIERK pathway together represent a likely mechanism
underlying the hyperreactivity to ET-1 that exists at the chronic stage oftype 2 diabetes in GK
rats 2i), In addition, Kamata's laboratory recently reported that the release ofvasoconstrictor
prostanoids including PGE2 that occurs upon agonist stimulation was increased in superior
mesenteric arteries from type 2 diabetic rats 26• 2D.
  There is a growing body of evidence concerning the roles played by PGs in diabetic
cardiovascular complications 2' 28). Cellular and animal models indicate that PGs are induced
under diabetic conditions, have proatherogenic effects and also mediate the actions of growth
factors and cytokines 28). Further, it is known that many PGs have specific vasoactive
propenies, thereby contributing to the local regulation ofvascular tone 2' 28). Indeed, earlier
reports had (a) proposed that alterations in the vascular metabolism ofPGs might play a
crucial role in diabetes-associated changes in local vasoregulatory mechanisms 30) and (b)
found that in mesenteric arteries isolated from type 1 diabetic dogs, exogenous arachidonic
acid led to thromboxane A2-mediated contraction, whereas in those from control animals, it
caused prostacyclin-dependent dilatation 3i). In aortas from type 2 diabetic mice,
phenylephrine-induced contraction has been found to be reduced and acetylcholine
(ACh)-induced relaxation to be enhanced by the nonselective cyclooxygenase (COX)
inhibitor indomethacin, suggesting agonist-induced release ofvasoconstrictor PGs 32).
Moreover, in type 2 diabetic mice, the basal tone of skeletal muscle arterioles is increased due
to an enhanced COX-2-dependent production ofvasoconstrictor PGs 33).
  The above background indicates not only that vasoconstrictor prostanoids are important for
the development ofdiabetic vasculopathy but also that a proper understanding ofPGE2-
61
mediated responses and signaling in diabetic arteries is indispensable ifeffective preventive
and therapeutic approaches are to be devised against the development ofdiabetic vascular
complications.
  The main aim ofthe present study was to test my basic hypothesis that the vasoconstrictor
effects ofPGE2 are enhanced in the type 2 diabetic GK rat. This is a highly inbred strain of
Wistar rats that spontaneously develops type 2 diabetes 34) and offers a convenient model for
the study ofthat disease without the confounding effects ofobesity or hypertension 34) at the
chronic stage. I also hypothesized that EP3 receptor-mediated contraction might be enhanced
in such rats via increased activation of the PKC5 pathway. I used superior mesenteric arteries
because my previously found that prostanoid release in response to agonists is increased in
such arteries isolated from GK rats, indicating that PGE2 signaling is likely to be important in
setting vascular tone 26). To test my hypotheses, I performed functional studies as well as
experiments to identify some ofthe molecular mechanisms involved,
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Reagems
  NG-nitro-L-arginine (L-NNA) and an antibody against B-actin were purchased from Sigma
Chemical Co. (St. Louis, MO, USA), while PGE2, sulprostone, sc19220, an antibody against
EP3 receptor and the relevant blocking peptide were from Cayman (Ann Arbor, MI, USA).
Acetylcholine (ACh) chloride was purchased from Daiichi Sankyo Pharmaceuticals (Tokyo,
Japan), while rottlerin and G06976 were from Calbiochem-Novabiochem (La Jolla, CA,
USA). L-NNA was dissolved in HPLC grade water, while PGE2, sulprostone, sc19220,
rottlerin and G06976 were first dissolved in DMSO. All concentrations are expressed as the
final molar concentration ofthe base in the organ bath. Horseradish peroxidase (HRP)-linked
secondary antimouse or antirabbit antibody was purchased from Promega (Madison, WI,
USA), antibodies against PKC6 and phospho-PKC6 (Thr505) were from Cell Signaling
Technology (Danvers, MA, USA) and antibodies against phospho-caldesmon (Ser534 for ratl
the corresponding human residue being Ser789) and caldesmon were from Abcam (Cambridge,
MA, USA).
Animals and experimental design
  Male Wistar control rats and GK rats were obtained at 4 weeks old (Clea, Tokyo, Japan).
The experimental design was approved by the Hoshi University Animal Care and Use
Committee, and all studies were conducted in accordance with the "Guide for the Care and
Use ofLaboratory Animals", published by the US National Institutes ofHealth, and with the
" Guide for the Care and Use of Laboratory Animals" adopted by the Committee on the Care
and Use ofLaboratory Animals ofHoshi University (accredited by the Ministry of Education,
Culture, Sports, Science, and Technology, Japan). All animals were allowed a standard
laboratory diet (MF; Oriental Yeast Industry, Tokyo, Japan) and water ad libitum. The
experiments described here were performed when the rats were 3744 weeks old.
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Measurement ofblood glucose
  Plasma glucose was measured by using a commercially available enzyme kit (Wako
Chemical Company, Osaka, Japan).
Vascularfunctionat study
  Vascular isometric force was measured as in previous papers 2i' 24'2D. After euthanasia, the
superior mesenteric artery was rapidly removed and immersed in oxygenated, modified
Krebs-Henseleit solution (KHS). This solution consisted of 1 18.0 mM NaCl, 4.7 mM KCI,
25.0 mMNaHC03, 1.8 mM CaCl2, 1.2 mMNaH2P04, 1.2 mM MgS04 and 11.0 mM glucose.
The artery was carefu11y cleaned of all fat and connective tissue and ring segments 2 mm in
length were suspended by a pair of stainless steel pins in a well-oxygenated (950/o 02-50/o
C02) bath containing 1O ml of KHS at 370C. The rings were stretched until the optimal
resting tension (1.0 g) was reached, which value was derived from preliminary length-active
tension curves 2i' 24-2D. They were then allowed to equilibrate for at least 1 h. Force generation
was monitored by means of an isometric transducer (model TB-6 1 1 T; Nihon Kohden, Tokyo,
Japan).
  For vasocontraction studies, PGE2 (1O-9-1O-5 M) or the EPIfEP3 agonist sulprostone
(1o-9.1o-5 M) ii7 i3•35•36) was added cumulatively to the organ bath until a maximal
response was obtained. To avoid the influence ofNO on the contractile response, I obtained
all data for the concentration-response curves in the presence of the NOS inhibitor L-NNA
(1o-4 M) 2i'26), except when endothelium-denuded preparations were used. To study the role
ofthe EPI receptor in the PGE2- and sulprostone-mediated responses obtained under NOS
inhibition, we generated concentration-response curves for PGE2 and sulprostone in the
presence of 10-5 M sc19220 (selective EPI antagonist ii'3D). To study the roles played by
PKCa and PKCP in PGE2-induced contractions, such contractions were obtained in the
presence of 1O-6 M Go6976 (PKCalB inhibitor i2' 38)). To study the role ofPKC6 in the PGE2-
and sulprostone-induced contractions, these were obtained in the presence of 1O-6 M rottlerin
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(PKC6 inhibitor i2)). After the addition of sufficient aliquots ofa given agonist to produce the
chosen concentration, a stable response was allowed to develop before the addition of the next
dose ofthe same agonist. When required, removal ofthe endothelium from arterial segments
was achieved by infusing a 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
solution (CHAPS, O.1O/o, for 60 s), followed by flushing out with KHS. The inability ofACh
to relax these segments confirmed the success ofthis procedure, as reported previously 2i' 26).
Finally, the wet weight ofthe mesenteric ring was measured. This weight was slightly but
significantly lower in the GK (1.02 Å} O.03 mg; n = 65) group than in the Wistar (1. 19 Å} O.03
mg; n = 67, P Åq O.OO1) group.
Mestern btoM'ng
  The protein levels ofEP3 receptor, phospho-PKC6 (Thr505), total PKC6,
phospho-caldesmon (Ser534), total caldesmon and B-actin were quantified using an
immunoblotting procedure, essentially as described before 2i' 26). Superior mesenteric arteries
from control and diabetic rats were isolated, cleaned of fat, dissected and frozen in liquid
nitrogen. To investigate the expression ofphospho-PKC6 or that ofphospho-caldesmon in
such mesenteric arteries upon sulprostone stimulation, mesenteric arterial rings were
incubated with KHS containing 1O-4 M L-NNA at 370C for 30 min and then exposed to 1O-5
Msulprostone or vehicle (water) for 10 min (phospho-PKC6) or 30 min (phospho-caldesmon).
Mesenteric arterial protein extracts (20 pg) were applied to 100/o SDS-PAGE and transferred
to polyvinylidene difluoride membranes. Blots were incubated with anti-EP3 (1 : 500),
anti-phospho-PKC6 (Thr505) (1 : 1,OOO), anti-PKC6 (1 : 1,OOO), anti-phospho-caldesmon
(ser534 for rat; the corresponding human residue being Ser789) (1 : 1,OOO) or anti-caldesmon
(1 : 1,OOO) antibody and anti-B-actin (1 : 5,OOO) antibody. Detection was achieved using a
HRP-conjugated IgG followed by enhanced chemiluminescence. Band intensity was
quantified by densitometry. Results were normalized to P-actin and are shown relative to
control (vehicle-treated Wistar). The specificity ofthe EP3 antibody was assessed using
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blocking peptide according to the manufacturer's instructions.
Statistieal analysis
  The contractile force developed by rings of superior mesenteric artery is shown here in
grams of tension per milligram oftissue. Concentration-response curves were fitted using a
nonlinear interactive fitting program (Graph Pad Prism5.0; Graph-Pad Software, Inc., San
Diego, CA, USA), Data are shown as means Å} SE. Statistical analysis ofthe concentration-
response curves was performed using two-way analysis ofvariance (ANOVA) for repeated
measures. For comparisons between groups, data were analyzed using ANOVA with a post
hoc Bonferroni test or Student's t test. Western blot data were analyzed by one-sample t test or
one-way ANOVAwith a post hoc Bonferroni test. Values ofPÅqO.05 were considered
statistically significant.
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                              Abbreviations
ACh, acetylcholine; ANOVA, analysis ofvarience; BP, blocking peptide; CHAPS,
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate solution; COX,
cyclooxygenaseJ DMSO, dimethylsulfoxide; EC, endothelial cell; EDCF,
endothelium-derived contracting; EDRF, endothelium-derived relaxing; GK, Goto-Kakizaki,
HRP, Horseradish peroxidase; KHS, Krebs-Henseleit solution; L-NNA, NG-nitro-L-arginine;
NO, nitric oxide; NOS, NO Synthase; PGs, prostaglandins; PGE2, prostaglandin E2; PKC,
protein kinase C; PVDF, polyvinylidene difluoride; SE, standard error; SDS-PAGE, sodium
dodecyl sulfate-polyacrylamide gel electrophoresis;
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Results
Blood glueose and body weight
  At the time ofthe experiment (when the rats were 37-44 weeks old), GK rats displayed a
higher blood glucose (non-fasted values) than control Wistar rats (442.0 Å} 20.3 mg dL-i; n =
20 vs. 166.5 Å} 6.2 mg dL-i; n =2 O, PÅqO.OOI). The body weight ofthe GK rats was lower
than that of the Wistar rats (386.2 Å} 6.9 g; n == 20 vs. 615.0 Å} 15.5 g; n = 20, PÅqO.OO1).
PGEr and sulprostone-indueed responses in superior mesenteric artei v
  NO plays an important role in the regulation ofvascular tone and negatively modulates
contraction, leading to complexities in analyzing the signaling pathways in the vasculature in
some situations 2i' 26' 39'4i). To mask any putative NO component in the present vasoconstrictor
responses, I performed functional experiments in the presence ofa NOS inhibitor (1O-4 M
L-NNA). This inhibits both basal and agonist-•induced NOS activities. In that condition,
cumulative administration ofPGE2 (1O-9-1O-5 M) (Fig. 3-IA) or sulprostone (10-9-lo-5 M)
(Fig. 3-IB) induced concentration-dependent contraction in superior mesenteric arterial rings,
whether they were from GK or Wistar rats. In the presence ofL-NNA, the PGE2-induced and
sulprostone-induced contractions were each greater in rings from GK rats than in those from
Wistar rats (Fig. 3-IA and B). Likewise, the PGE2-induced contraction was greater in
endothelium-denuded rings from GK rats than in those from Wistar rats (Fig. 3-1C). To
determine which receptor (EPI or EP3) mediates the above contractile responses, we
investigated the effect ofa selective EP1 receptor antagonist (Fig. 3-IA and B). That
antagonist, sc19220 (1O-5 M), did not affect the PGE2-induced vasocontraction in either group
(Fig. 3-IA) and had a significant suppressive effect on the sulprostone-induced
vasocontraction only at 1O'6 M in the GK group and only at 1O-5 M in the Wistar group (Fig.
3-IB). It should be noted that in the presence ofthat EP1 antagonist, the PGE2d- and
sulprostone-induced vasocontractions were still greater in rings from GK rats than in those
from Wistar rats. These results suggest that the augmentations ofthe PGE2-induced and
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sulprostone-induced contractile responses seen in superior mesenteric arteries from GK rats
were attributable to activation ofthe EP3 receptor rather than ofthe EP1 receptor.
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Fig. 3-1. Effects ofEPI antagonist on PGE2-induced vasocontraction in superior mesenteric
artery rings from GK rats. Concentration-response curves for PGE2 (A) and sulprostone (B) in
the presence of 10-4 M LNNA or 10-4 M L-NNA plus 1O-5 M sc19220, and for PGE2
following endothelial denudation (O. Data, which are shown for superior mesenteric arteries
from diabetic GK and control Wistar rats, are means Å} SE (n = 5 or 6). *P Åq O.05, GK vs.
Wistar. fp Åq O.05, Wistar vs. Wistar sc19220. tPÅqO.05, GK vs. GK sc19220. XP Åq O.05, GK
sc 1 9220 vs. Wistar sc 1 9220.
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Effeet ofPKCi inhibition on EP3 receptor-inducedvasocontraetion
  The published evidence suggests that PKC6 plays an important role in vasocontraction in
various arteries i2'38' 42). Therefore, we investigated the relative contribution made by PKC6 to
EP3 receptor-mediated responses in diabetic superior mesenteric arteries under NOS
inhibition. The PGE2-induced contraction was significantly reduced by the selective PKC6
inhjbitor rottlerin (lO-6 M) (Fig 3-2A) but not by the PKCalP jnhjbjtor Gb6976 (1O-6 M) (Fjg
3-2B). Similarly, the sulprostone-induced contraction in GK mesenteric arteries was
significantly reduced by rottlerin (Fig. 3-2C).
AA.
g oXltar
gt' iSivvtsSr9ill:/El-
 {e.
g
o
     -9 " -7 -6
           Peq {lag M)BSZ GK
 egi. ;:tKtin'ect6g76
5i.
ge.
-
5
s
-8 -7 -6
 peq{togM} "
cA2.
 S (M(
s" t. .'Q' Gl:1,!":l'etiierla
g
    " VYIstarRottierin
  t'i,
o
-g
" -7 -6Sdipmtone (tog M) - 5
Fig. 3-2. Efilects ofPKC6 inhibitor or PKCalP inhibitor on PGE2-induced vasocontraction in
superior mesenteric artery rings.from GK rats. Concentration-response curves for PGE2 (A,
B) or sulprostone (q. All experiments were performed in the presence of 10-4 M L-NNA
with or without either 10-6 M rottlerin (A, C) or 1O-6 M Go6976 (B). Data, which are shown
for superior mesenteric arteries from diabetic GK and control Wistar rats, are means Å} SE (n
=
 5 or 6). *P Åq O.05, GK vs. Wistar. fp Åq O.05, Wistar vs. Wistar rottlerin. tP Åq O,05, GK vs.
GK rottlerin. tP Åq O.05, GK rottlerin vs. Wistar rottIerin.
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Sulprostone-inducedphosphoi vlation ofPKCi is increased in GK mesenteric arteiv
  Since PKCs are phosphorylated in the process of activation, the level ofphosphorylation
indicates their activation level 43). To assess PKC6 activity, I examined the levels of
phosphorylated PKC6 (Thr505) (p-PKC6). Westem immunoblots were obtained from superior
mesenteric arteriesafter sulprostone (1O-5 M for 1O min) or vehicle treatment (Fig. 3-3),
Although total PKC6 expression in those arteries was similar between GK and Wistar rats
(Fig. 3-3C), the p-PKC6 level induced by sulprostone stimulation was significantly greater in
the GK than in the Wistar group (Fig. 3-3B), These data suggest that an increase in PKC6
activity due to increased phosphorylation at Thr505 may contribute to the augmentation of
EP3-mediated contraction seen in superior mesenteric arteries from GK rats.
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Fig. 3-3. Phosphorylation ofPKC6 by EP3 agonist in superior mesenteric arteries from
diabetic GK rats. Phospho-PKC6 (Thr505) and total PKC6 protein contents were assessed by
Western blotting in superior mesenteric artery rings stimulated with sulprostone (10-5 M), or
treated with vehicle, for 1O min, (A) Representative blots are shown for phosphorylation of
PKC6 at Thr505 (p-PKC6) and for PKC6 in Wistar and GK arterial rings stimulated with
                                                            -4sulprostone or without stimulation (vehicle), in each case in the presence of 10
                                                              ML-NNA,
Bands for phospho-PKC6 (B) or total PKC6 (C), or for B-actin, were quantified as described
in "Methods", ratios being calculated for the optical density ofphospho- or total PKC6 over
that of3-actin, Data are means Å} SE from eight experiments. "P Åq O.05, GK vs, corresponding
Wistar.
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Sulprostone-inducedphosphorylan'on ofcntdesmon is increased in superior mesenteric
arteriesfrom GK ras
  Caldesmon has been extensively studied as a modulator of smooth muscle contraction and
phosphorylation ofcaldesmon in intact smooth muscle increases in parallel wnh isometric
force 44' 45). Moreover, previous studies have clearly demonstrated that PKCs phosphorylate
caldesmon in various tissues and cells 46' 4". Therefore, I examined whether the
sulprostone-stimulated expression ofphosphorylated caldesmon (Ser789) protein in superior
mesenteric arteries might be increased in the GK group. immunoblot analysis ofsulprostone
(10-5 M for 30 min)-stimulated and vehicle-treated arteries from Wistar and GK groups (using
anti-phospho-caldesmon and anti-caldesmon antibodies) allowed detection ofimmunoreactive
proteins (Fig. 3-4). For both h-caldesmon and l-caldesmon, the phosphorylated levels induced
by sulprostone were significantly greater in the GK than in the Wistar group (Fig. 3-4B and
D), whereas total caldesmon levels did not differ between those groups (Fig. 3-4C and E).
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Fig. 3-4. Phosphorylation ofcaldesmon by EP3 agonist in superior mesenteric arteries from
diabetic GK rats. Phospho-caldesmon (Ser789) and total caldesmon protein contents were
assessed by Western blotting in superior mesenteric artery rings stimulated with sulprostone
(1O-5 M), or treated with vehicle, for 30 min. (A) Representative blots are shown for
phosphorylation ofcaldesmon at Ser789 (p-caldesmon) and for caldesmon in Wistar and GK
arterial rings either stimulated with sulprostone or without stimulation (vehicle), in each case
in the presence of 1O-4 M L-NNA. Bands for phospho-h-caldesmon (B), total h-caldesmon (C),
phospho-l-caldesmon (D) or total l-caldesmon (E), and for B-actin, were quantified as
described in "Methods", ratios being calculated for the optical density ofphospho- or total
caldesmon over that of P-actin. Data are means Å} SE from four or five experiments. *P Åq O.05,
GK vs, corresponding Wistar,
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Expression ofEP3 receptor in smperior mesenteric arteries
  Conceivably, an alteration in EP3 receptor expression could underlie the enhanced EP3
receptor-mediated vasocontraction seen in the GK artery. Accordingly, I investigated EP3
receptor protein expression in superior mesenteric arteries by Western blotting (Fig. 3-5). The
EP3 polyclonal antibody detected multiple bands (Fig. 3-5A). Importantly, these multiple
bands disappeared completely when the primary antibody was pre-incubated with the
appropriate antigenic peptide (Fig. 3-5A). The protein expression ofEP3 (Fig. 3-5A; analyzed
sum ofall multiple bands) in superior mesenteric arteries was similar between Wistar and GK
rats (Fig. 3-5B).
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Fig. 3-5. Protein expression of EP3 receptor in superior mesenteric arteries from Wistar and
diabetic GK rats. (A) Representative Western blots for EP3 receptor and 6-actin. Asterisk
indicates band disappeared after incubation ofthe primary antibody for EP3 receptor with the
appropriate blocking peptide. BP blocking peptide. (B) Bands were quantified as described in
" Methods", ratios being calculatedfor the optical density of EP3 receptor over that of P-actin.
Data are means Å} SE from six experiments.
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Discussion
  The principal inference to be drawn from the present study is that the contractile response
to PGE2 exhibited by the superior mesenteric artery is enhanced in type 2 diabetic GK rat
when the animal is at the chronic stage of its disease. In addition,Ifound that: 1) the
PGE2-induced vasocontraction is mediated by EP3, not EP1, receptors; 2) the augrnentation of
the EP3 receptor-mediated vasocontraction in the GK artery is attributable to increased
activation ofPKC6 and increased phosphorylation ofcaldesmon and 3) the superior
mesenteric arterial expression ofEP3 receptors did not differ between the nondiabetic Wistar
and diabetic GK groups.
  The GK rat, a model oftype 2 diabetes without the confounding effects of hypertension or
obesity 34), was used here at the later stage ofdiabetes [viz. 3744 weeks old] because
long-term type 2 diabetic conditions are associated with severe diabetic cardiovascular
complications. In fact, numerous reports have indicated that abnormal vascular reactivity is
exhibited by vessels taken from GK rats at the chronic stage oftheir diabetes 2i-26• 48'50).
However, no previous study has investigated how PGE2-induced vasocontraction per se, or
the relevant downstream pathways or receptor expressions, might be altered in a longterm
diabetic state. In the present study, I found that in a given group (viz. GK or Wistar), the
PGE2-induced vasocontraction was similar between NOS inhibitor treatment and endothelial
denudation (Fig. 3-IA vs. C), and that it was enhanced in the GK artery in each condition.
These findings demonstrate a) that the PGE2-induced vasocontraction observed here is not
endothelium-dependent and b) that a diabetes-related enhancement of this response can occur
in the absence ofendothelium and without altered NO production. The above does not, of
course, exclude the possibility that NO might be a suppressor ofPGE2-mediated
vasocontraction in intact arteries. In this context, it should be noted that in the same artery
(superior mesenteric) isolated from the same type 2 diabetes model (GK rats), there have been
shown to be impairments ofthe endothelium-dependent relaxations induced by various
agonists 24• 25).
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Receptors involved
  Four subtypes ofEP receptor (viz. EPI, EP2, EP3 and EP4) have been described i'3'5). Of
these, the EPI and EP3 subtypes mediate vasocontraction i'3'5' iO' i2' i3). Therefore, I focused
on the contractile responses to PGE2 and sulprostone (EPIIEp3 agonist ii' i3• 35• 36)) and on the
effect ofsc19220 (EPI antagonist ii'3D) on such responses in mesenteric arteries isolated
from Wistar and GK rats. In the present study, the EP1 antagonist had almost no effect on the
PGE2- and sulprostone-induced vasocontractions. Indeed, those vasocontractions were
increased in the GK (vs. Wistar) mesenteric artery both in the absence and in the presence of
the EP1 antagonist. These results suggest that vasoconstrictor responses mediated by the EP3
subtype are enhanced in the GK mesenteric artery. This idea is supported by the published
finding ofKobayashi et al. i2) that an EP3 agonist, but not an EP1, EP2 or EP4 agonist,
induced vasocontraction in a main branch ofthe rat mesenteric artery.
  In my Western blotting analysis, multiple bands were detected for the EP3 receptor in
homogenates of superior mesenteric artery from either group. This is consistent with the
results obtained in a previous study using a different vessel ii). Multiple bands for GPCRs
including EP receptors could result from oligomerization ofthe receptor, post-transcriptional
modification ofthe protein or the formation ofheteromers with other proteins 5'5i-54).
Although the exact conformations ofthe EP3 receptors present in diabetic mesenteric arteries
remains unclear, I think that differences in the downstream pathway are more likely to explain
the differences in the vasocontractions induced by the present agonists between GK and
Wistar rats because the total expression ofthe EP3 receptor was similar between the two
groups of rats.
Pnthways involving PKCi
  PKC is a well-characterized enzyme involved in myogenic constriction and
agonist-induced vascular smooth muscle contraction 55-58). In vascular smooth muscle, a
number ofsignal transduction cascades activated by physiological agonists are regulated by
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PKC and, indeed, PKC phosphorylates several substrates associated with vascular smooth
muscle contraction 56' 58' 59). The PKC isozymes are subdivided into cPKC (ct, BI, 6II and y),
nPKC (6, e, e, and n) and aPKC (g, X). Among these isozymes, PKCct, PKC6 and PKCg are
known to mediate vasocontraction. Recently, Kobayashi et al. i2) demonstrated in rat
mesenteric artery: a) that EP3 receptor-mediated vasocontraction was inhibited by
pretreatment with a general PKC inhibitor or with a PKC6 inhibitor but not with a cPKC
inhibitor and b) that EP3 agonism induced PKC6 phosphorylation. In the present study, the
PGE2- and sulprostone-induced vasocontractions were blocked by rottlerin (selective PKC6
inhibitor i2)) but not by Go6976 (selective PKCa16 inhibitor i2' 38)). Moreover, the
phosphorylation ofPKC6 induced by sulprostone was increased in mesenteric arteries from
GK rats vs. those from Wistar rats (Fig. 3-3). These data suggest that the enhanced
EP3-induced vasocontraction observed here in diabetic arteries was due to increased PKC6
activities. However, I should point out that there is controversy in the literature over the
activities ofrottlerin including the selectivity of its PKC inhibition 69). Nevertheless, on the
basis ofpublished documentation (e.g., Refs. i2' 46)), I believe that it is a sufficiently selective
PKC6 inhibitor for the present purpose and indeed that a better agent is not currently
available.
Pathways involving ealdesmon
  One ofthe major target proteins for PKC that is important in vascular contraction is
caldesmon 4D. Two isoforms ofcaldesmon exist: a high molecular weight isoform,
h-caldesmon, which is restricted to smooth muscle, and a low molecular weight isoform,
l-caldesmon, which is expressed both in nonmuscle cells and in dedifferentiated smooth
muscle cells 44' 47' 6i). Caldesmon, an actin filament-associated protein, seems to be implicated
in the control ofvasocontraction through inhibition ofactin-activated myosin Mg2+-ATpase 62'
63). Phosphorylation ofcaldesmon by PKC has been shown to impair this inhibition 62' 63).
Phosphorylation ofcaldesmon results in vascular contraction 64) and, indeed, in the present
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study, the phosphorylation ofboth h- and l-caldesmon induced by sulprostone was increased
in arteries from GK (vs. Wistar) rats. These data suggest that the observed augmentation of
EP3 receptor-mediated vasocontraction in the GK mesenteric artery may be attributable to
increased phosphorylation of caldesmon. This idea is consistent with previous reports a) that
phosphorylation of caldesmon in smooth muscle cells is associated with increased isometric
force 44' 45) and b) that the phosphorylation ofcaldesmon via activation ofPKC6 in cerebral
arteries is associated with augrnented vasocontraction 46).
F"nctionaYphysiological signi:ticance
  PGE2 is present in many tissues and has been implicated in a myriad ofpathological
conditions. For instance, it was reported some years ago that vascular endothelial growth
factor (VEGF) is expressed at high levels in diabetic retinas and is involved in the
pathogenesis ofdiabetic retinopathy 65). Moreover, other studies showed that increased
expression ofPGE2 leads to upregulation ofVEGF expression 66) and that the retinal
production ofPGE2 is increased in diabetic rats 6D. Kamata's laboratory previous studies
demonstrated that production ofPGE2 is increased in diabetic arteries 26' 2D and the present
data demonstrate that PGE2-induced vasocontraction is enhanced in superior mesenteric
arteries from diabetic rats. As yet, I cannot say whether or not the abnormal PGE2 signaling
present in GK arteries resulted from the long-term nature ofthe rats' diabetes or, indeed,
whether such abnormal signaling might be the cause of such diabetic vascular complications
as impairments ofthe peripheral/splanchnic circulation. At this point, I can only say that
therapeutic regulation ofPGE2 signaling warrants further investigation as a candidate for the
prevention ofdiabetic vascular complications. Finally, activation ofPKC appears to be a key
feature ofdiabetes mellitus and, indeed, enhanced PKC activation has been strongly
implicated in the pathogenesis ofdiabetic vascular complications 68' 69). The development of
isozyme-specific PKC inhibitors is a feasible proposition and offers the exciting prospect of
blocking pathways involved in the initiation and progression ofdiabetic vasculopathy.
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Chapter 4
Mechanisms underlying reduced P2Yi-receptor-mediated relaxation in superior
   mesenteric arteries from long-term streptozotocin-induced diabetic rats.
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Introduction
  Endothelial cells are important for the regulation ofvascular tone and reactivity under both
physiological and pathophysiological conditions. They perform such roles by responding to
neurohumoral mediators and mechanical forces with the release ofavariety of
endothelium-derived factors i' 2' 3). Endothelial dysfunction is a phenomenon common to a
number of cardiovascular diseases, including diabetes i' 2' 4-6). Among the vascular
complications associated with diabetes is an impairment ofvascular reactivity to various
neurotransmitters within the macro- and microvasculature i' 2' 7' 8). For instance, there is an
accumulating body ofevidence to indicate that the relaxation responses induced by various
agents are abnormally weak in diabetic patients and in animal models ofdiabetes, such as the
streptozotocin (sTz)-induced diabetic rat i' 7' 9-i2). Therefore, a proper understanding of the
mechanisms underlying the endothelial dysfunction present at various stages and in various
types ofdiabetes is important for preventive and therapeutic approaches against the
development of diabetic vascular complications.
  Nucleotides play important roles not only in intracellular nucleic acid synthesis and energy
supply but also, once released into the extracellular space, in various biological responses
involved in the control ofcellular functions i3-i8). Extracellular triphosphate (e.g. ATP and
UTP) and diphosphate (e.g. ADP and UDP) nucleotides are released into tissue fluids and
plasma from aggregated platelets and from activated endothelial cells and leucocytes in
response to various proinflammatory stimuli, cell death and tissue damage i3' i9). They
generate a number ofresponses within the vasculature, such as platelet activation and changes
in smooth muscle contraction and dilatation in various arteries iS) 20' 2i). Extracellular
nucleotides activate cell-surface receptors, namely purinoceptors, which can be divided into
metabotropic G-protein-coupled P2Y receptors and ionotropic P2X receptors 22'25). so far,
seven P2X receptors (i.e. P2Xi-7) and eight P2Y receptors (i.e. P2Yi, 2, 4, 6, ii-i4) have been
characterized 22-26). A fu11 understanding of signalling by purinoceptors remains elusive
because receptor distribution differs among tissues 22-26) and because most purinoceptors are
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able to respond to several nucleotides, resulting in a situation in which multiple receptors
have overlapping ligand preferences 26). In particular, the mechanisms that might alter
purinoceptor signalling in the diabetic vasculature remain unclear at present.
  Activation ofendothelial P2 receptors is important for nucleotide-induced vasodilatation iS'
20' 2i). Three major endothelium-derived relaxing factors (EDRFs) can be involved in such
responses, depending on the species and vessel-type considered: these factors are nitric oxide
(NO), prostacyclin and endothelium-derived hyperpolarizing factor (EDHF) i5' 27-29). p2yi
and P2Y2 receptors are thought to be responsible for adenosine 5'-diphosphate sodium salt
(ADP)- and ATPfUTP-induced vasodilatation in most vessels 30-32). I and others have found
that nucleotide-induced arterial responses are altered in models ofvarious cardiovascular
diseases, such as hypertension and diabetes i4'2i'34'3D. However, whether
P2Yi-receptor-mediated vasodilatation is normal or abnormal in diabetic states remains
unclear.
  Although diabetes can affect purinergic sigrLalling in various tissues and cells i3), no
previous study has examined P2Yi-receptor-mediated vasodilatation in a long-term diabetic
state. I therefore designed the present study to investigate the long-term effect ofdiabetes on
the dilator responses to P2Yi-receptor agonists in the rat isolated superior mesenteric artery. I
hypothesized that P2Yi-receptor-mediated relaxation would be impaired in such arteries from
STZ-induced diabetic rats because ofalterations in NO signalling. I also asked whether
superior mesenteric arteries from control and diabetic rats might exhjbit differential
expressions ofthe P2Yi receptor.
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Reagents
  Adenosine 5'-triphosphate disodium salt (ATP), ADP, phenylephrine (PE),
NG-nitro-L-arginine (L-NNA), MRS2179 and an antibody against B-actin were all purchased
from Sigma Chemical (St. Louis, MO, USA), while 2-methylthio-ADP trisodium salt
(2-MeSADP) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Acetylcholine chloride (ACh) was purchased from Daiichi-Sanlcyo Pharmaceuticals (Tokyo,
Japan). Suramin was obtained from Wako Pure Chemical Industries (Osaka, Japan). All drugs
were dissolved in HPLC grade water, except for suramin and MRS2179 (dissolved in DMSO).
All concentrations are expressed as the final molar concentration ofthe base in the organ bath.
Horseradish peroxidase (HRP)-linked secondary anti-mouse or anti-rabbit antibody was
purchased from Promega (Madison, WI, USA). Antibody against endothelial NO synthase
(eNOS) was from BD Biosciences (San Jose, CA, USA), while those against phospho-eNOS
(serii77 or Thr495) were from Cell Signalling Technology (Danvers, MA, USA) and that
against P2Yi receptor was from Abcam (Cambridge, MA, USA).
Animals and experimental design
  The experimental design was approved by the Hoshi University Animal Care and Use
Committee, and all studies were conducted in accordance with `Guide for the Care and Use of
Laboratory Animals', published by the US National lnstitutes ofHealth, and with `Guide for
the Care and Use ofLaboratory Animals' adopted by the Committee on the Care and Use of
Laboratory Animals ofHoshi University (accredited by the Ministry ofEducation, Culture,
Sports, Science, and Technology, Japan). Male Wistar rats (8 weeks old and 190-230 g body
weight) received a single injection via the tail vein of STZ 65 mg kg-i dissolved in a citrate
buffer, as reported previously ii'i2' 38' 39). Age-matched control rats were injected with the
buffer alone. Food and water were given ad libitum. The experiments described here were
performed when the rats were 58-65 weeks old (i.e. at 50--57 weeks after the injection).
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Measurement of blood glucose
  Plasma glucose was measured by using a commercially available enzyme kit (Wako
Chemical Company, Osaka, Japan) as described previously i2' 39).
Functionnt study
  Vascular isometric force was measured as in previous papers ii'38' 39). After killing, the
superior mesenteric artery was rapidly removed and immersed in oxygenated, modified
Krebs-Henseleit solution (KHS). This solution consisted of(in millimolar) 1 18.0 NaCl, 4.7
KCI, 25.0 NaHC03, 1.8 CaC12, 1.2 NaH2P04, 1.2 MgS04 and 1 1.0 glucose. The artery was
carefu11y cleaned ofall fat and connective tissue and ring segments 2 mm in length were
suspended by a pair of stainless steel pins in a well-oxygenated (950/o 02-50/o C02) bath of
KHS at 37 OC. The rings were stretched until an optimal resting tension of 1.0 g was loaded,
which was optimal for inducing a maximal contraction ii), then allowed to equilibrate for at
least 1 h. Force generation was monitored by means ofan isometric transducer (model
TB-61 1T; Nihon Kohden, Tokyo, Japan).
  Cumulative concentration-response curves were obtained to ADP (1O-8-10-5 M),
2-MeSADP [10-9- 10-5 M; selective P2Yi agonist `O)] and ATP (10-8-10-` M) in superior
mesenteric arteries precontracted with 10'6 M PE. The submaximal contraction developed in
response to 1O-6 M PE was similar between diabetic and control groups, based on preliminary
experiments. To study the roles ofendothelium and NO in ADP-induced relaxation, I
constructed concentration-response curves to ADP I) after endothelial denudation and 2) in
the presence of 10-4 M L-NNA [NOS inhibitor ii'35)]. To study the role ofthe P2--receptor
pathway in ADP-induced relaxation, such relaxations were examined in the presence of 1O-4
M suramin [nonselective P2 receptor antagonist 35)] or 10'5 M MRS2179 [selective P2Yi
antagonist 40' 4i)]. After the addition of sufficient aliquots ofthe agonist to produce the chosen
concentration, a plateau response was allowed to develop before the addition ofthe next dose
ofthe same agonist. When required, removal ofthe endothelium from arterial segments was
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achieved by infusing a 3-[(3-cholamidopropyl)dimethylammonio]- 1-propanesulphonate
solution (CHAPS, O. 1 O/o, for 60 s), which was subsequently flushed out with KHS; the
inability ofACh to relax these segments confirmed the success ofthis procedure.
Measurement ofNO metabolites IniM'te (7VOi ) and nitrate (7V03-)1
  The effluent from a given tissue was sampled and assayed by the method described
previously 42). Each superior mesenteric artery was cut into transverse rings 4 mm in length.
These were placed in KHS [well-oxygenated (950/o 02-50/o C02)] at 37 OC and then treated
with ADP (3 Å~ 10-6 M) for 15 min. The amount ofNOx was calculated as follows:
ADP-stimulated NOx [nmolll5 (min) g (weight ofthe mesenteric artery)]. The concentrations
ofnitrite plus nitrate (NOx) in the KHS and in the NOx standard (Eicom, Kyoto, Japan) were
measured using an automated NO detectorlhigh-performance liquid chromatography system
(EN020; Eicom).
Mestern bloin'ng
  The protein levels ofP2Yi receptor and ofphosphor-eNOS (Serii77 and Thr495) and total
eNOS were quantified using an immunoblotting procedure, essentially as described before 42).
Superior mesenteric arteries from control and diabetic rats were isolated, cleaned of fat,
dissected and frozen in liquid nitrogen. To investigate the expression ofphospho-eNOS in
such arteries upon ADP stimulation, mesenteric arterial rings from a given rat were incubated
with KHS [well-oxygenated (950/o Or50/o C02)] at 370 C and then exposed to 3 Å~ 10-6 M
ADP or vehicle (water) for 15 min. For the examination ofP2Yi-receptor expression, we used
tissues not used for drug-treatment experiments. Mesenteric arterial protein extracts (20 pg)
were applied to 1OO/o SDS-PAGE and transferred to polyvinylidene difiuoride membranes.
Blots were incubated with anti-P2Yi (56 kl)a; 1 : 500) 43), anti-phospho-eNOS (serii77) (14o
ld)a; 1 : 500) `4), anti-phospho-eNOs (Thr`95) (140 ld)a; 1 : 500) `5), anti-eNOS (140 kl)a; 1 :
1OOO) 44) or anti-B-actin (42 kDa; 1 : 5000) antibodies, with detection being achieved using a
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HRP-conjugated IgG followed by enhanced chemiluminescence. Band intensity was
quantified by densitometry. Results were normalized to the b-actin expression. To assess
ADP-induced eNOS phosphorylation (at Serii77 or Thr495), I calculated the ratio of the optical
density ofphosphorylated eNOS or total eNOS in ADP-stimulated or nonstimulated (basal)
samples, in each case over that ofthe corresponding B-actin band. These values are presented
as the fold increase in phosphorylated eNOS from basal. In some experiments involving
detection ofphospho-eNos (serii77 or Thr495), eNOS and B-actin proteins, the same
membranes were stripped (phosphorylated eNOS at Serii77 and phosphorylated eNOS at
Thr495 were loaded on different gels). For P2Yi-receptor and B-actin protein detection, the
different samples (nondrug-treated) were loaded on to different gels.
Statistical anntysis
  Experimental vasorelaxation values are expressed as a percentage ofthe maximal
contraction induced by PE in a given segment, Concentration-response curves were fitted
using a nonlinear interactive fitting programme (Graph Pad Prism 5.0; GraphPad Software,
San Diego, CA, USA). Data are expressed as means Å} SE. Statistical Statistical analysis ofthe
concentration-response curves was performed using two-way analysis ofvariance (ANOVA)
for comparisons between groups. For other comparisons between groups, data were analysed
using ANOVA with a post hoc Bonferroni test or Student's t-test, Western blot data were
analysed by 1-sample t-test, Student's t-test, or one-way ANOVA. Values ofP Åq O.05 were
considered statistically significant.
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                             Abbreviations
2-MeSADP, 2-methylthio-ADP; ACh, acetylcholine; ANOVA, analysis ofvarience; ADP,
adenosine diphosphate; ATP; adenosine triphosphate; CHAPS,
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate solution; DMSO,
dimethylsulfoxide; EC, endothelial cell; EDRF, endothelium-derived relaxing; eNOS,
endothelial NOS; HRP, Horseradish peroxidase; KHS, Krebs-Henseleit solution; L-NNA,
NG-nitro-L-arginine; NO, nitric oxide; NOS, nitric oxide Synthase; NOx, nitric oxide
metabolites; NBT, nitro-blue tetrazolium; P2 receptor, purinoceptor; PE, phenylephrine;
PVDF, polyvinylidene difluoride} STZ, streptozotocin; SE, standard error; SDS-PAGE,
sodium dodecyl sulfate--polyacrylamide gel electrophoresis; SMC, smooth muscle cell,
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Results
Body weight and btood glucose
  At the time of the experiment (when the rats were 58-65 weeks old), the body weight of the
diabetic rats (326.4 Å} 19.5 g; n = 15) was lower than that ofthe age-matched nondiabetic
control rats (690.1 Å} 12.8 g; n= 18, PÅqO.OO1). All STZ rats (non-fasted) exhibited
hyperglycaemia (544.2 Å} 24.1 mg dL-'; n = 15), their blood glucose levels being significantly
higher than those ofthe control rats (also non-fasted) (148.9 Å} 4.1 mg dL-i; n == 18, P Åq
O.OOI).
P2Yl-agonist-induced reltvcation is redueed in superior mesenterie arteriesfrom diabetic
rats
  When the contraction induced by PE (1O-6 M) had reached a plateau, ADP (1O-8-1O-5 M),
2-MeSADP (10"9-10-5 M) or ATP (10-8-10-4 M) was added cumulatively. In rings from
age-matched control rats, ADP (1O-8-1O-5 M) induced a concentration-dependent relaxation
and this relaxation was significantly impaired in rings from diabetic rats vs. those from
control rats (Fig. 4-IA). Likewise, the selective P2Yi agonist 2-MeSADP 40' 46) induced a
relaxation that was reduced in the diabetic group vs. the control group (Fig. 4-IB). On the
other hand, the ATP induced relaxation was similar between the two groups (Fig. 4-1q.
  To try to confirm that the ADP-induced vasodilatation was indeed mediated by the
P2Yi-receptor, I investigated the effect ofa selective P2Yi-receptor antagonist on the
ADP-induced response (Fig. 4-ID). MRS2179 (1O'5 M) completely blocked the ADP-induced
relaxation in each group (Fig. 4-ID) and therefore abolished the difference between the
groups (Fig. 4-ID). These results suggest that P2Yi-mediated vasodilatation is impaired in
superior mesenteric arteries from long-term STZ-induced diabetic rats.
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Fig. 4-1. P2Yi-agonist-mediated relaxation is impaired in diabetic superior mesenteric arteries
Concentration-response curves for adenosine 5'-diphosphate sodium salt (ADP) (A),
2-MeSADP (B) and adenosine 5'-triphosphate disodium salt (ATP) (C År and for ADP in the
presence ofa selective P2Yi-receptor antagonist (1O-5 M MRS2179) (D). Data, which are
shown for superior mesenteric arteries from diabetic and control rats, are means Å} SE, with
the number ofdeterminations being shown within parentheses. "P Åq O.05 vs. control.
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Effects ofendothelial denudation andIVOS inhibition on ADP-induced vasodilatation
  Published evidence suggests that ADP-induced relaxation is mediated by the activation of
the endothelium and NO signaling 46' 4D. Therefore, I assessed the relative contributions made
by these factors to ADP-induced responses in diabetic superior mesenteric arteries.
ADP-induced relaxation was completely blocked by endothelial denudation (Fig. 4-2A) and
also by treatment with the NOS inhibitorL-NNA (10-4 M) (Fig. 4-2B). Consequently, each of
those manoeuvres abolished the difference between the groups, suggesting that a paucity of
endothelium-derived NO signalling is largely, or even solely, responsible for the defect in
ADP-induced relaxation in the long-term STZ-induced diabetic superior mesenteric artery.
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Fig. 4-2. Effects ofendothelial denudation and NOS inhibitjon on adenosine 5'-diphosphate
sodium salt (ADP)-induced relaxation in superior mesenteric arteries obtained from control
and diabetic rats. Little or no ADP-induced relaxation was evident following endothelial
denudation (A) or treatment with NOS inhibitor (1O-` M L-NNA) (B) in either group. Data are
means Å} SE, with the number of determinations being shown within parentheses.
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ADP-inducedIVOproduction is reduced in superior mesenteric arteriesfrom diabetic rats
  Together, previous reports 3i) and the present data (Fig. 4-2) suggest that the NO pathway
plays an important role in ADP-mediated vasodilatation. To examine whether the difference
in ADP-induced vasodilatation between the two groups ofrats might be mediated by altered
NO production, we measured the release ofNO metabolites (i.e. N02- and N03-) from rings
treated with ADP (Fig. 4-3). The ADP (3 Å~ 10'6 M)-induced NOx (N02- plus N03-) level
was significantly lower for the diabetic group than for the controls.
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Fig. 4-3. Levels ofNO metabolites (NOx; NOi + N03-) after stimulation of superior
mesenteric artery rings with 3 Å~ 10-6 M adenosine 5'-diphosphate sodium salt (ADP) for 15
min. Data are means Å} SE, with the number of determinations being shown within
parentheses. *P Åq O.05 diabetic vs. control.
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Expression ofeAIOS andADP-induced elVOSphosphoiylation in superior mesenteric
    .artenes
  In the regulation of eNOS activity by agonists, signal transduction depends not only on
Ca2+lcalmodulin but also on eNOS phosphorylation by various kinases 48'5i). Regulation of
eNOS is achieved by phosphorylation ofmultiple sites in the protein. Phosphorylation at
serii77 stimulates eNos activity 48-5i), whereas phosphorylation at Thr495 inhibits its activity
45). Therefore, I examined I) whether ADp might promote phosphorylation ofeNOS at serii77
and 2) whether eNOS dephosphorylation at Thr495 might be weaker in the diabetic group than
in the age-matched controls. Immunoblot analysis ofADP (3 Å~ 10-6 M for 15 mjn)-stimulated
and nonstimulated (basal) arteries from control and diabetic groups (using
anti-phospho-eNOS and anti-eNOS antibodies) allowed detection of immunoreactive proteins
(Fig. 4-4). First, I examined the expression ofphosphorylated eNOS (Ser'i") (Fig. 4-4A-D).
The densitometric ratio of eNOS to P-actin tended (i.e. not significantly) to be increased in
mesenteric arteries from diabetic rats in both ADP-stimulated and nonstimulated conditions
(Fig. 4-4B). In arteries from the control group, the densitometric ratio ofphosphorylated
eNOS (at Serii77) to B-actin was significantly increased by ADP-stimulation (vs. basal) (Fig.
4-4C). However, there was no such difference between ADP-stimulated and basal in
mesenteric arteries from diabetic rats (Fig. 4-4C). As the apparent level oftotal eNOS protein
differed between the groups (Fig. 4-4B), I compared the groups in terms oftheir fold increase
from the basal (i.e. nonstimulated) level (Fig. 4-4D). The value ofthe fold increase in
phosphorylated eNOS (at Serii77) was significantly smaller in arteries from the diabetic group
than in those from the control group (Fig. 4-4D). I next evaluated the ADP-stimulated eNOS
phosphorylation (Thr495) levels (Fig. 4-4E-H). The densitometric ratio of eNOS to P-actin
tended (i.e. not significantly) to be increased in the diabetic arteries (vs. their controls) (Fig.
4-4]F). Furthermore, the phosphorylated eNOS (Thr495) expression (Fig. 4-4G) and the value
of the fold increase in phosphorylated eNOS (Thr495) (Fig. 4-4H) did not differ between the
diabetic and age-matched control groups in either the ADP-stimulated or ADP-nonstimulated
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Fig. 4-4. Phosphorylation ofendothelial NO synthase (eNOS) at Serii77 by adenosine
5'-diphosphate sodium salt (ADP) is reduced in superior mesenteric arteries from diabetic rats.
phospho-eNos (serii77 and Thr495) and total eNOS protein contents were assessed by
Westem blotting in superior mesenteric rings treated with ADP (3 Å~ 1O-6 M) or vehicle
(basal) for 15 min. (A, E) Representative blots are shown for phosphorylated eNOS (Ai Serii77,
E: Thr495), as well as for eNOS, in control and diabetic arterial rings, in each case with
(`ADP') or without (`Basal') stimulation with ADP. (B, n Bands for eNOS and B-actin
quantified as described in Materials and Methods, ratios being calculated for the optical
density ofeNOS over that ofB-actin. (C, G) Quantification ofeNOS phosphorylation at
serii77 (c) and at Thr495 (G). Ratios were calculated for the optical density ofphosphorylated
p-eNOS over that ofB-actin. (D, H) Quantification ofeNOS phosphorylation (D: Serii77, Hi
Thr495, see Materials and Methods): y-axis shows fold increase (vs. corresponding basal),
Data are means Å} SE, with the number ofdeterminations being shown within parentheses. *P
Åq O.05 vs, corresponding control.
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Expression ofP2 Yi receptor in superior mesentericarteries
  Alterations in P2Yi receptors have been reported in various pathophysiological states and
during ageing 52' 53). To investigate the possible mechanism underlying the reduced
ADP-mediated vasodilatation seen here in diabetic arteries, I used Westem blotting. In
superior mesenteric arteries, the protein expression ofP2Yi receptors did not differ between
the diabetic and age-matched control groups (Fig, 4-5),
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Fig. 4-5. Protein expression ofP2Yi receptor in superior mesenteric arteries from control and
diabetic rats. Left: representative Western blots for P2Yi receptor and b-actin. Right: bands
quantified as described in Materials and Methods, ratios being calculated for the optical
density ofP2Yi receptor over that ofP-actin. There was no difference between the groups.
Data are means Å} SE, with the number of determinations being shown within parentheses.
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Discussion
  The principal, fundamental finding made in the present study was that in superior
mesenteric arteries isolated from STZ-induced diabetic rats, the relaxation response to ADP is
impaired, at least when the animals have had a disease state oflong duration. In addition, I
found that: 1) the ADP-induced vasodilatation in that artery was mediated by the P2Yi
receptor and NO sigrialling; 2) the ADP-induced NO production was reduced in the diabetic
mesenteric arteries (vs. the age-matched controls); 3) the ADP-induced stimulation of eNOS
is dysfunctional in the diabetic mesenteric arteries; and 4) the protein expression ofthe P2Yi
receptor did not differ between the control and diabetic groups.
  Among the purinoceptors, the P2Yi and P2Y2 receptors are thought to be responsible for
nucleotideinduced vasodilatation in most tissues 20' 30). The P2Xi, P2X2, P2X3, P2X4, P2Y4
and P2Yii receptors evidently mediate NO production and subsequent vasodilatation 20• 54'56).
In the present study, the vasodilator responses to the preferential P2Yi-receptor agonist ADP
23' 25) and the selective P2Yi-receptor agonist 2-MeSADP 23' 25' 40) were each impaired in the
diabetic mesenteric arteries. The ADP-induced vasodilatation was completely blocked in each
group - and the intergroup difference in this response therefore completely abolished - by the
selective P2Yi-receptor antagonist MRS2179 23' 25'4i). These results strongly suggest that a
defect in P2Yi-receptormediated relaxation is present in superior mesenteric arteries in
long-term diabetic rats. By contrast, the relaxation induced by ATP did not differ between the
control and diabetic groups, and MRS2179 had no significant effect on the ATP induced
relaxation in either group (data not shown). ATP may activate endothelial purinoceptors
related to vasodilatation in addition to the P2Yi receptor 20' 54-56). Therefore, the apparent lack
ofa difference in the ATP induced relaxation between the two groups may be attributable to
compensatory changes mediated by other purinoceptors andlor EDRFs.
  Endothelial NO synthase, a key determinant ofvascular homoeostasis 2' 49• 57'58), is a
Ca2'lcalmodulin-dependent enzyme that is activated in response to stimulation ofa number of
different Ca2'-mobilizing cell-surface receptors 2' 49' 57'58). Some studies have indicated that
                                   94
activation ofthe P2Yi receptor in vascular endothelial cells induces Ca2'-independent NO
production. 3i' 59). Regulation of eNOS is known to be achieved via phosphorylation of
multiple sites within the protein 2' 49' 57' 58). The two most thoroughly studied sites are the
activation site serii77 and the inhibitory site Thr495 60). As activation ofP2Yi receptors on
endothelial cells leads to phosphorylation and activation of eNOS 50' 5i' 60), I focused on effects
on both ofthose sites in the ADP-stimulated superior mesenteric artery. I found that in the
long-term diabetic superior mesenteric artery, although the expressions of eNOS protein and
nonstimulated eNOS phosphoryIation (at Serii77) tended (nonsignificantly) to be increased,
the ADP-stimulated fold increase in phosphorylated eNOS (at Serii77) was reduced. In
contrast, the ADP-stimulated phosphorylation of eNOS at Thr495 did not differ between the
two groups. Whether the finding that the nonstimulated Serii77 phosphorylation tended to be
increased in the diabetic arteries is of any importance remains unclear. What these results do
suggest is that ADP-induced stimulation ofeNOS is dysfunctional, not eNOS activity per se,
in the present diabetic arteries. Indeed, ADP-stimulated NO production was reduced in the
diabetic arteries (vs. the age-matched controls) despite an unchanged P2Yi-receptor
expression. Kamata's laboratory and others have suggested that in diabetes, the vasodilator
response to an agonist such as ACh is impaired as a consequence ofendothelial dysfimction
(e.g. reduced phosphorylation ofeNOS at serii77) i' 44). In superior mesenteric arteries from
STZ-induced diabeticWistar rats (58-65 weeks old) and their age-matched controls, I found
that the ACh-induced relaxation was similar between the two groups (unpublished
observation), suggesting that eNOS activation by ACh in that artery was not affected by the
diabetes. On the other hand, the ACh-induced EDHF-type relaxation was impaired in the aged
diabetic group vs. the age-matched control group (unpublished observation). Therefore, in
aged diabetic rats, the contributions made by NO- and EDHF-type relaxations appear to differ
by agonist, and we believe that the present findings may be important for the elucidation of
the pathophysiological roles played by extracellular nucleotides in later-stage diabetes. The
regulation ofeNOS by phosphorylation at Serii77 has been studied extensively. Many protein
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kinases-including AMP-activated protein kinase 60), cyclic AMP-dependent protein
kinaselprotein kinase A 62), Akt 48' 63) and PLC 64), as well as cyclic GMP-dependent protein
kinase 65) - act, at least in part, through this Serii77 phosphorylation site. However, the precise
mechanisms by which such kinases are associated with P2Yi-mediated eNOS
phosphorylation in long-term diabetic states remain unclear at present. Consequently, future
studies should seek to identify the molecular mechanisms by which eNOS phosphorylation is
induced by P2Yi-receptor stimulation in diabetic mesenteric arteries.
  Recently, the ecto-nucleotidase NTPDase 1 has been reported to be important in controlling
endothelial P2Y-receptor-dependent relaxation 66). Extracellular nucleotides are metabolized
by NTPDase 1 and this enzyme could promote desensitization ofthe P2Yi receptor. The
protein expression oftotal NTPDase 1 between diabetic rats in superior mesenteric arteries
did not differ and age-matched control rats (data not shown). Although previous studies on
diabetes have reported increased NTPDase 1 activity 67' 68), the extent of any NTPDase 1
contribution to the promotion ofP2Yi-receptor desensitization remains unclear. In this
context, further research will be required to establish the extent to which this enzyme might
be associated with the impaired ADP-mediated vasodilation present in long-term diabetes.
  A number ofprevious studies using STZ-induced diabetic rats have observed abnormalities
ofresponses to various vasoactive substances in a variety ofblood vessels i' 69' 70). In such
studies, diabetes is normally induced at a relatively young age in rats by giving STZ, and the
effects of STZ-induced diabetes are generally observed for a period of 8-20 weeks. In such
studies, Ralevic and colleagues foimd that I) at 8 weeks after the induction ofSTZ diabetes in
rats, sensory-motor-nerve-evoked vasodilatation was severely attenuated, although
sympathetic nerve and endothelial functions were normal 7i) and 2) at 12 weeks after the
induction of STZ diabetes in rats, there was both pre-junctional impairment of sympathetic
neurotransmission and impaired endothelial function in mesenteric arterial beds 72). On the
other hand, vascular reactivity to agonists in long-term diabetic states has seldom been
investigated 73'75). Some reports have suggested that in long-term diabetic states, the dynamic
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equilibrium for various nucleotides (i.e. between generation and metabolism) undergoes
alteration both systemically and locally i5' 76' 7D. Although the present study has clearly
demonstrated that P2Yi-mediated vasodilatation is impaired in superior mesenteric arteries in
long-term STZ diabetic rats, further studies will be required focusing, for instance, on the
time-course ofchanges in the reactivity to P2Yi agonists and in NO signaling in the diabetic
state to establish causal relationships.
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                              Conclusions
 In the present study, I have investigated the mechanisrns underlying the
diabetes-related changes in the extracellular n"cleotides-induced respomses in superior
mesenteric arteries from rats. I found that the COX-mediated and
endothelium-dependent contraction could be enhanced by not only ACh but also by
extracellular nucleotides. I also found that the enhancement of extracellular
nucleotide-induced contraction was attribute to the increased release ofPGE2 from
endothelial cells and to the enhancement of EP3 receptor-mediated vasoconstriction via
activation of the PKC6 pathway in smooth muscle cells. I believe that these findings play
an important role in make a great contribution to the exploration of therapeutic targets
for diabetes-associated vascular diseases.
The above findings lead to the following conclusions;
(Chapter 1) I found that pravastatin treatment (viz. 4-week treatment of OLETF rats already at
the chronic stage) normalized EDCF-induced contraction by suppressing Rho-kinase activity
and by promoting antioxidant activity in the superior mesenteric arteries from rats at the
chronic stage oftype 2 diabetes. The vasculoprotective actions ofpravastatin in OLETF
mesenteric arteries can be largely attributed to the suppression ofEDCF signalling by a
cholesterol-independent pleiotropic effect.
  The present study provides a credible explanation for the beneficial effects of statins on the
vascular system in type 2 diabetes.
(Chapter 2) The findings ofthis study indicate 1) abnormal release ofprostanoids from
endothelium and 2) increases in the expressions ofphospho-cPLA2, COX-1, and COX-2 in
superior mesenteric artery from diabetes rats. The aberrant nucleotide-induced contractions
and the levels ofPGE2 and PGF2. release in diabetes rats could be normalized by losartan
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treatment via suppression ofcPLA21COX activity I suggest that the diabetes-related
enhancement ofnucleotides-mediated vasoconstriction is due to P2Y receptor-mediated
activation ofthe cPLA21COX pathway and that losartan normalizes such contractions by
suppressing this pathway.
(Chapter 3) I investigated the mechanisms underlying the enhancement of PGE2-induced
contraction in superior mesenteric arteries from type 2 diabetic rats. Among the PGs, PGE2,
one ofthe important factors in EDCF, has been reported to be a vasoconstrictor mediated by
the EPI and EP3 receptors in smooth muscle. In superior mesenteric arteries, 1)
PGE2-induced vasocontraction was mediated by EP3, but not by EPI receptor; 2) the
augmentation of the EP3 receptor-mediated vasocontraction in the GK artery was attributable
to activation ofPKC6 and increased phosphorylation ofcaldesmon and 3) no difference
observed in the expression ofEP3 receptor between diabetic and control groups. My data
suggest that the diabetes-related enhancement ofEP3 receptor-mediated vasocontraction
results from activation ofthe PKC5 pathway. Alterations in EP3 receptor-mediated
vasocontraction may play an important role in the abnormal vascular functions in chronic
diabetic states.
(Chapter 4) I found that I) the ADP-mediated vasodilation in superior mesenteric artery was
induced by the P2Yi receptor and NO signalling, 2) the ADP-induced NO production was
reduced by dysfunction of eNOS activity (as evidenced by reduced the fold increase in eNOS
phospholation at Serii77 with no difference in fold increase in eNOS phospholation at Thr495)
in the STZ-induced diabetic superior mesenteric arteries and 3) the protein expression of
P2Yi receptor was not different between the control and diabetic groups. These results
suggest that P2Yi-receptor-mediated vasodilatation is impaired in superior mesenteric arteries
from long-term type 1 diabetic rats.
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